DK150690B - Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse - Google Patents
Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse Download PDFInfo
- Publication number
- DK150690B DK150690B DK639871AA DK639871A DK150690B DK 150690 B DK150690 B DK 150690B DK 639871A A DK639871A A DK 639871AA DK 639871 A DK639871 A DK 639871A DK 150690 B DK150690 B DK 150690B
- Authority
- DK
- Denmark
- Prior art keywords
- enzyme
- antibodies
- reaction
- specific binding
- hcg
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
- G01N33/541—Double or second antibody, i.e. precipitating antibody
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/971—Capture of complex after antigen-antibody reaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
- Y10S436/818—Human chorionic gonadotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
150690 ø
Det er kendt, at en komponent i reaktionen mellem et specifikt binderprotein og det tilsvarende bindelige stof kan bestemmes ved, at man inkuberer en af de omhandlede komponenter forsynet med en markør i en reaktionsblanding, som i det mindste indeholder den anden komponent, 5 og derpå iværksætter en adskillelse mellem den mærkede komponent, som henholdsvis er og ikke er bundet til dens bindingspartner og endelig bestemmer markøren i mindst en af de to fremkomne fraktioner. Fordelingen af den mærkede komponent over de to fraktioner er et mål for den mængde af den søgte komponent, som er til stede i prøven. Der 10 kan beskrives tre systemer, i hvilke den ovennævnte fremgangsmåde kan anvendes, a) antistoffer som specifikke binder-proteiner og de tilsvarende antigener som bindelige stoffer. Stoffer, som kan bestemmes 150690 . 2 på denne måde, er bl, a. proteinhormoner og deres antistoffer eller virus-antigener og deres antistoffer, b) antistoffer som specifikke binder-proteiner og haptener som bindeligt stof. Her defineres hap-tenerne som proteinfri stoffer, der kan reagere med antistoffer uden 5 at være i stand til at inducere dem. Stoffer, som kan bestemmes i et sådant system, er bl.a. steroidhormoner og vitaminer, c) proteiner, som i legemet virker som receptor- eller transport-molekyler som specifikke binder-proteiner og stoffer, som er bundet af dem som binde-lige stoffer. Dette system er f.eks. egnet til bestemmelse af ste-10 roidhormoner, men også af thyroxin og triiodthyronin, vitamin B12, den intrinsicole faktor og det adrenocorticotrope hormon.
De vigtigste punkter i de beskrevne analysemetoder er anvendelsen af en markør og adskillelsen af den mærkede komponent i en fraktion, 15 som er bundet, og en fraktion, som ikke er bundet til den tilsvarende komponent.
Fra beskrivelsen til dansk patentansøgning nr. 5462/71 kendes en fremgangsmåde, ved hvilken der anvendes enzymmærket komponent i forbindel-20 se med en kvantitativ immunologisk bestemmelse. Ved denne kendte fremgangsmåde sker adskillelsen mellem flydende og fast fase ved gelfiltrering, men denne metode er upraktisk og kan ikke give nogen pålidelig og let bestemmelse. Ved metoden kan immunokomponenter kun bestemmes i en koncentration på 50-100 nanogram pr. milliliter.
25
Fra beskrivelsen til dansk patentansøgning nr. 2812/67 kendes endvidere en fremgangsmåde, ved hvilken der gøres brug af uopløseliggjorte antistoffer overfor proteiner eller peptider, som er antigener, i en radio-immun bestemmelse. Radiaktive atomer anvendt som markører er 30 f.eks. 131j, 125^, 14^, 3^, 5?Co Denne fremgangsmåde er kendetegnet ved en høj følsomhed. Imidlertid er denne fremgangsmåde begrænset til institutter, hvor det nødvendige specielle apparatur er tilgængeligt.
Adskillelsesmetoderne kan opdeles på følgende måde: 35 a) Fremgangsmåder afhængige af forskellen i fysiske egenskaber mellem den ikke bundne, mærkede komponent og dens kompleks med bindings-partneren, såsom gel-filtrering, elektroforese, saltudfældning og absorption til dekstran-overtrukket trækul.
40 b. Den såkaldte fastfase-metode, ved hvilken den ene komponent allerede i forvejen er bragt i uopløselig form ved tværbinding eller ved 3 150690 covalent binding eller fysisk adsorption til en fast bærer, c) Den såkaldte dobbelte antistof«metode,ifølge hvilken det dannede kompleks, antigen (eller hapten)«antistof udfældes ved hjælp af antistoffer over for antistoffet i komplekset, hvilken fremgangsmåde 5 kun er kendt fra systemer, i hvilke antistoffer i opløst form kommer i betragtning«
Medens de under a) og c) omtalte fremgangsmåder er relativt komplicerede, lider de under b) omtalte af den ulempe, at en reaktions-10 komponent, når den bringes i uopløselig form, som regel vil mindske sin affinitet til reaktions-partneren. Imidlertid er en høj affinit« vigtig for tilvejebringelse af et følsomt prøvesystem.
Ifølge opfindelsen har man fundet en fremgangsmåde til bestemmelse 15 af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et koblingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det 20 specifikke binderprotein (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), hvilken fremgangsmåde er ejendommelig ved, at man yderligere anvender . uopløseliggjo.rte antistoffer oVér for det-< specif ikke binder-protein,·' og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller 25 faste fase af reaktionsblandingen. Denne fremgangsmåde muliggør bestemmelse af komponenter, der er til stede i en koncentration på 1-1C nanogram pr. milliliter.
I den foreliggende beskrivelse bruges begreberne conjugat og enzym-30 conjugat synonymt for koblingsproduktet af det bindelige stof og enzymet.
Det bindelige stof kan opdages og bestemmes ved, at man sammenbringer den ukendte prøve eller en fortyndingsserie af samme med en kendt 35 mængde af et conjugat af det stof, der skal bestemmes, og et enzym og med en mængde specifikt binderprotein i afhængighed af den mængde enzym-conjugat, som tilsættes. Derpå tilsættes en mængde, fortrinsvis et overskud af de antistoffer, der er gjort uopløselige over for det specifikke binder-protein, så at hele enzym-conjugatet, som har 40 reageret med binder-proteinet, ved hjælp af dette protein bliver koblet til disse uopløselige antistoffer. Jo mere bindeligt stof der ex 4 150690 til stede i prøven, jo mindre enzym-conjugat vil reagere med det specifikke binder-protein og sluttelig komme i den uopløselige fase. Resultatet bliver, at mere ubundet enzym-conjugat forbliver i den flydende fase og på simpel måde kan bestemmes der. Det specifikke 5 binder-protein kan bestemmes ved, at man inkuberer prøven eller fortyndingsserier af denne med en kendt mængde enzym-conjugat og med en mængde af de over for det specifikke binder-protein uopløselig-gjorte antistoffer. Enzymaktiviteten kan kun finde sted i den uopløselige fase, hvis conjugatet har reageret med det specifikke bin-10 der-protein, d.v.s. jo mere specifikt binder-protein, der er i prøven, jo mindre bundet enzym-conjugat vil forblive i den flydende fase.
Den beskrevne analyse-metodes følsomhed kan varieres ved at ændre mængderne af reagenserne. Imidlertid er den mængde enzym-conjugat, 15 som kan anvendes, begrænset nedefter af kravet om, at dets enzymaktivitet kan måles på rimelig måde, hvorfor analyse-metodens følsomhed har sin begrænsning. Den minimalt målelige enzym-aktivitet er bl. a. afhængig af naturen af det enzym, der anvendes ved koblingen, og af substratets natur og endelig af enzym-reaktionens 20 inkubationstid. Fremdeles indvirker det specifikke binder-proteins affinitet stærkt på bestemmelsens følsomhed. Ved en analyse-metode af høj følsomhed kræves specifikke binder-proteiner med en høj affinitet.
25 Mængderne af de for en bestemmelse nødvendige reagenser må fastlægges ad empirisk vej.
Til bestemmelsen af det bindelige stof må mængden af enzym-conjugatet bestemmes ved hjælp af enzymaktiviteten. Derpå inkuberes denne mængde 30 med en fortyndingsserie af det specifikke binder-protein til bestemmelse af den nødvendige mængde af dette protein. Fortrinsvis vælger man en mængde specifikt binderprotein, som kan binde 50-90% af enzym-conjugatet. Til sidst undersøger man, hvorvidt den ønskede følsomhed så er blevet nået, idet man undersøger en fortyndingsserie af 35 det stof, der skal undersøges ved metoden.
Til bestemmelsen af det specifikke binder-protein må der angående doseringen af enzym-conjugatet tages hensyn til dettes aktivitet, som skal kunne bestemmes med rimelig nøjagtighed.
s 150690
De antistoffer over for det specifikke binder-protein, der er gjort uopløselige, tilsættes fortrinsvis i overskud ved de to bestemmelses-måder. Disses dosering bestemmes ved forudgående forsøg.
5 Denne fremgangsmådes fordele over for de kendte er, at kombinationen af "Dobbelt Antistof" og "Fast Fase"-metoden, i det følgende af bekvemmelighedsgrunde betegnet DASP-metoden, frembyder adskillige fordele over for de kendte fremgangsmåder. Således er udførelsen af den nye fremgangsmåde, d.v.s. tilførsel af uopløseliggjorte anti-10 stoffer over for det specifikke binder-protein, inkubation, centrifugering og måling, meget simpel, doseringen er ofte lettere end ved fast-fase-metoderne, fordi det er tilstrækkeligt at tilsætte et overskud af uopløst materiale, hvorimod man ved fast-fase-metoderne skal bruge en nøjagtigt udmålt mængde af det faste materiale. Frem-15 deles er affiniteten hos binder-proteinet til det bindelige stof ikke svækket af bindingen til bærermaterialet, således som det kan være tilfældet ved fast-fase-metoden. En yderligere fordel over for den sidste fremgangsmåde er den hurtige ligevægt-indstilling hos reaktionen mellem det specifikke binder-protein og det bindelige stof 20 (begge i opløsning). En yderligere fordel består i, at ved DASP- fremgangsmåden kan det uopløseliggjorte antistof, nedenfor betegnet immunoadsorbenten, bruges i ethvert system, i hvilket man bruger antistoffer som specifikke binder-proteiner, forudsat at disse antistoffer er præpareret i de samme dyrearter. På den anden side, for 25 ethvert antigen eller hapten, der skal bestemmes efter fast-fase-metoden, skal antistofferne gøres uopløselige. Den dobbelte antistofmetode er meget følsom over for relativt små ændringer i saltkoncentrationerne, pH og lignende, som gør en vidtgående kontrol af betingelserne nødvendig. Yderligere kræver metoden tilføjelse af 30 "bærer"-γ-globulin og følgelig meget andet antistof til opnåelse af et immunt precipitat. Foruden at være en mere enkel fremgangsmåde fører DASP-metoden, som ikke kræver "bærer"-γ-globulin, til besparelse af materialer. Endelig skal det nævnes, at en dobbelt antistoflignende adskillelse anvendt ved transport- eller receptor-proteiner 35 ikke er mulig, da der ikke kan fremskaffes et "bærer"-protein til dette formål. Fremgangsmåden ifølge opfindelsen frembyder derfor en enestående lejlighed i denne henseende.
Fremgangsmåden ifølge opfindelsen kan let gøres automatisk. Det er 40 principielt muligt at bringe reaktionskomponenterne sammen straks _ t t _ . i _ j . _ -? , » t_ _ i i ^ ^___ ^ r Λ__i · T __ __ i i____ 6 150690 man dog fortrinsvis de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens, idet det har vist sig, at bestemmelsen derved får en højere følsomhed.
5
Ved fremgangsmådens anvendelse til bestemmelse af det bindelige stof går man af samme grund hensigtsmæssigt frem på den måde, at man først til prøven sætter det specifikke binder-protein og derpå enzym-con-jugatet og til sidst de uopløselige antistoffer over for det speci-fikke binder-protein.
Det for opfindelsen nødvendige reagens, d.v.s. koblingsproduktet af antigen, hapten eller det bindelige stof med enzymet, kan fremstilles på kendt måde. Disse fremgangsmåder kan også bruges til at bin-15 de et hapten eller et lavmolekulært bindeligt stof til et enzym, forudsat at et af stofferne har en eller flere aminogrupper og det andet en eller flere carboxylgrupper. Hvis det sidste ikke er tilfældet, er det muligt at indføre den ønskede gruppe i molekylet, som skal kobles, ved hjælp af en kendt organokemisk proces. Der kendes 20 også fremgangsmåder til sammenbinding af amino- og carboxylgrupper, eventuelt ved at indføre en bro. Endelig kan komponenter som glutar-aldehyd, difluordinitrodiphenylsulfon og di- og tri-chloro-s-tria= zin ofte anvendes til den omhandlede kobling. Det kan blive nødvendigt at adskille de fremstillede enzymconjugater fra uomdannede stof-25 fer og fra stoffer, som er blevet inaktive. Til dette formål kan man benytte kendte fremgangsmåder, såsom udfældning med organiske opløsningsmidler, gelfiltration og centrifugering ved en vægtfyldegradient .
20 Valget af det enzym, der benyttes i koblingsproduktet, er bestemt ved et antal egenskaber hos enzymet. Naturligvis er det vigtigt, at enzymet er resistent over for koblingen med et andet molekyle, d.v.s. over for ændring af en eller flere aminosyre-sidekæder. Enzymets specifikke aktivitet er også af stor vigtighed. Da en mindre mæng-25 de enzym—conjugat behøver at tilføjes for at opnå en målelig enzympåvirkning, bliver undersøgelsessystemet mere følsomt. Fremdeles bør man foretrække de enzymer, hos hvilke en bestemmelse af aktiviteten kan foretages på en simpel måde, I første række bør man tage de enzymer i betragtning, for hvilke aktiviteten kan béstemmes kolorime-40. trisk, épektrofotometrisk eller fluorimetrisk. Sådanne bestemmelser 7 150690
Man kan bestemme aktiviteten af de, .enzymer kolorimetrisk, som katalyserer en reaktion, ved hvilken der. .opstår eller forsvinder et farvet stof, enten ved den primære eller den sekundære reaktion.
5 Som enzymer, der- kan" anvendes som den enzymatisk; aktive komponent i conjugater, skal nævnes catalase, peroxidase (3-glucoronidase, β-D-glucosidase, β-D-galactosidase, urease, glucose-oxidase, galactose-oxidase og alkalisk phosphatase.
10 Ved afslutningen af reaktionen mellem komponenterne og reagenserne kc man ifølge opfindelsen bestemme enzymaktiviteten i den flydende ellei den faste fase, eller i begge faserne af reaktionsblandingen. Det simpleste er imidlertid at bestemme enzymaktiviteten i den flydende fase, 15
De antistoffer, der er gjort uopløselige over for de specifikke binde proteiner, som også er vigtige reagenser for fremgangsmåden ifølge op findelsen, kan også fremstilles på kendt måde. Antistofferne kan fremstilles, idet man tager et renset præparat af det specifikke bin-20 der-protein eller af de proteiner, som har i det mindste delvis de sa me antigen-egenskaber som det specifikke binder-protein, og så injice rer dette på kendt måde i en anden dyreart end den, fra hvilken man fik det. Det behandlede dyrs serum eller gamma-globulin-fraktionen af dette kan gøres uopløseligt ved kryds-led-forbindelse med sådanne sto 25 fer som glutaraldehyd og chlormyresyre-ethylester eller ved binding t faste bærerpartikler enten fysisk eller adsorptivt eller kemisk ved dannelse af covalente bindinger. Som faste bærere kan anvendes sådanm stoffer som cellulose (ændret eller ikke), agarose, kryds-led-forbundi dekstran, polystyren og lignende. En covalent binding til disse stof· 30 fer af antistoffer kan foretages ved hjælp af sådanne stoffer som car: bodiimider, di- og tri-chloro-s-triaziner, glutaraldehyd, cyanogenbro-mid og f.eks. ved diazotering.
Fordelene ved fremgangsmåden ifølge opfindelsen til bestemmelse af 35 binderprotein opnås, hvis man anvender et overskud af uopløselige ant: stoffer, således at det specifikke binderprotein går helt over i den faste fase.
De former, i hvilke reagenserne kan anvendes, er mangfoldige. Den 40 enzym-conjugerede komponent i reaktionssysternet kan frysetørres eller 8 150690 opløses i en stødpude. Man kan også bruge en fast bærer, f,eks. en papirstrimmel imprægneret med conjugatet. Denne anvendes også til de nødvendige binder-proteiner.
Den uopløselige komponent kan bringes i form af partikler af forskellig størrelse, såsom granuler, flager, stave eller i form af en strimmel af et eller andet bæremateriale.
Opfindelsen angår endvidere en analysepakke til bestemmelse af * et specifikt binder-protein eller det tilsvarende bindelige stof ved den beskrevne fremgangsmåde, hvilken analysepakke er ejendommelig ved at den hovedsagelig indeholder: a) en kendt mængde conjugat af det bindelige stof og et enzym, ’ b) en kendt mængde binder-protein, hvis analysepakken skal anvendes til bestemmelse af det bindelige stof, c) én kendt mængde uopløseliggjorte antistoffer rettede imod det binderprotein, som er tilsat, eller som skal bestemmes, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
i
Analysepakken kan fremdeles indeholde de nødvendige yderligere midler til analysens udførelse, såsom reagensglas, pipetter og flasker med opløsninger.
Analysepakken kan særlig hyppigt og med særlig fordel anvendes til opdagelse og bestemmelse af et antigen eller et hapten, og til dette formål indeholder den i hovedsagen: a) en kendt mængde af et conjugat af antigenet eller haptenet og et enzym, b) en tilsvarende mængde af tilsvarende antistoffer, c) en kendt mængde uopløseliggjorte antistoffer, rettede imod de anvendte antistoffer, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
Når man anvender sådanne analysepakker til påvisning og bestemmelse af antistoffer, behøver man ikke de under b) nævnte antistoffer.
150690 9
En vigtig udførelsesform for en analysepakke ifølge opfindelsen er én ana-lysepakke til bestemmelse af de gonadotrope hormoner og særlig til bestem' melse af HCG (Human Chorionic Gonadotropin) som et middel til bestemmelse 5 af graviditet allerede på et meget tidligt stadium, hvilken analysepakke er ejendommelig ved, at den består af en beholder, der som væsentlige bestanddele i lyofiliserede lag indeholder: a) en bestemt mængde af et HCG-conjugat og et enzym, f.eks. HCG-peroxidase b) en bestemt mængde anti-HCG, c) en bestemt mængde uopløseliggjorte antistoffer oyer for anti-HCG sammei med et substrat til bestemmelse af enzymaktiviteten af det resterende HCG-enzym i den flydende fase.
Ved tilsætning af en vis mængde urin fra en formodet gravid kvinde, til 15 denne analyseblanding og ved at inkubere urinen med disse bestanddele dannes der en blanding af uopløseligt stof, idet den øvrige del indeholder det tilbageblevne opløselige HCG-enzym-conjugat. Mængden af det sidste afhænger af mængden af HCG i den undersøgte urin. Ved bestemmelse af enzymaktiviteten hos dette tilbageblevne HCG-enzym-conjugat kan man 20 fastslå, om urinen skyldes en gravid kvinde eller ej.
En fremgangsmåde, der fortrinsvis anvendes ved bestemmelsen af enzymaktiviteten, består i, at man bringer et indikator-papir imprægneret med enzymreagenser, f.eks, hvis der bruges en peroxidase, en H„09-forsyner så- 25 ^ ^ som urinstof-EL^,med et farvereagens såsom o-tolidin.
Ved korrekt valg af mængderne af hvert af reagenserne bliver det muligt at fastslå graviditet allerede på et meget tidligt stadium og på en simpel, hurtig og meget pålidelig måde, som kan udføres af en ikke opøvet 30 person.
150690 10
Eksempel 1.
Bestemmelse af det menneskelige chloriongonadotropin (HCG).
5 a) Fremstilling af HCG-HRP.
5 mg HCG og 20 mg peberrods-peroxidase (HRP) opløses i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Efter tilsætning af ko μΐ 25$ glutaraldehyd-ορløsning rystedes “blandingen i 2 timer ved stuetemperatur. Efter 5 minutters centrifugering ved 250 g fraktioneredes væsken over Sephadex G-200 i 0,05 M phosphat= stødpude med pH-værdien 6,2. Fraktionerne, hos hvilke den højeste enzymaktivitets $ var bundet af antistoffer overfor HCG brugtes under analysen.
15 b) Fremstilling af antistoffer overfor HCG.
Antistoffer overfor HCG indiceredes i kaniner som angivet af Schuurs et al. Acta Endocr. (Kbh) 59j 120,(1968).
c) Fremstilling af antistoffer overfor kanin-y-globulin.
2q Kanin-Y-globulin isoleredes fra normalt kanin-serum ved udfældning med l8$ w/v fast natriumsulfat. Antistoffer overfor dette fremstilledes ved immunisering af et får i overensstemmelse med følgende skemai 25 dag mængde Freud's adjuvans injektionsmåde 0 o,5 mg + intramuscular 1^· o,5 mg + intramuscular 28 1 mg + intramuscular b2 1 mg - intravenøs 3Q 56 1 mg - intravenøs den 70.dag blev fåret åreladt.
d) Fremstilling af immunoadsorbent-eellulose /får-anti-(kanin-γ-globu= 35 lin)7.
γ-globulinfraktionen af fåre-serumet beskrevet under c) fremstilledes ved udfældning med 165¾ w/v fast natriumsulfat. Efter vaskning optoges udfældningen i så meget 0,05 M borat-stødpude med pH-værdien 8,6, at den fremkomne proteinkoncentration udgjorte 10 mg/ml.
4Q 350 mg m-aminobenzyloxymethylcellulose opslemmedes i 50 ml destilleret 11 15069¾ vand og diazoteredes ved tilsætning af 10 ml 30$ saltsyre og dråbevis tilsætning af 10 ml 10$ NaDiK^-opløsning ved 0°C. Op-slemningen centrifugeres. Den vaskedes, og bundfaldet resuspendere-des i *+3 ml 0,05 M natriumborat med pH-værdien 8,6, derpå tilsattes 5 7 ml af den fremstillede γ-globin-opløsning. Blandingen omrørtes i 26 timer ved å-°C, hvorpå den centrifugeredes og vaskedes med 0,02 M phosphat-stødpude med pH-værdien 6,0.
e) Bestemmelse af HCG
10 Der fremstilledes en fortyndingsserie (32 -16-8-^-2-1-o,5-IU/ml) af HCG i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ v/v normalt fåreserum.
0,5 ml af hver af de HCG-indeholdende prøver inkuberedes med 0,1 ml kanin-(anti-HCG)-serum og 0,1 ml HCG-KRP-conjugat, begge i passen-15 de fortynding i eii halv time’ved stuetemperatur. Derpå tilsatte 0,3 ml af immunoadsorbenten (10 mg/ml) fremstillet ifølge d),og den fremkomne blanding omrørtes i en time ved stuetemperatur. Efter centrifugering bestemtes enzymaktiviteten: resten ved at blande 0,5 ml .
af denne væske med 1,5 ml substrat (10μ1 30$ ^.$2 °& 20 mg 5-amino--20 salicylsyre i 150 ml 0,02 M phosphatstødpude med pH-værdien.6,0), og efter 30 minutter ved 25°C måltes ekstinctionen ved 1+60 mm.
På denne måde påvistes det, at det var muligt at opdage en HCG-koncentration fra 0,5 til lIU/ml i prøven. Ved denne metode kunne man også undersøge urinprøver. Undersøgelsen er derfor egnet til 25 en graviditetsprøve. Forholdet til en eksisterende undersøgelsesmetode, en hæmaglutinations-·inhibitions-prøve var god. Det påvistes muligt at forøge systemets følsomhed ved anvendelse af en pre-incubation. Her incubereres prøven først med antiserumet og derpå tilsattes HCG-HRP-conjugatet.
30
Eksempel II.
Bestemmelse af insulin og anti-insulin.
a) fremstilling af insulin-(glucose-oxidase).
35 Der opløstes 5 mg grise-insulin af 25 mg glucose-oxidase i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,5. Hertil sættes 5 μΐ glutaraldehyd-opløsning, hvorefter blandingen rystedes i 90 minutter ved stuetemperatur. Blandingen fraktionereres over Sephadex 150690 12 G-200 i 0,05 M phosphat-stødpude med pH-værdien 6,5.De .fraktioner, af hvilke den højeste procentiske enzym-aktivitet kunne hindes af antistoffer overfor insulin, anvendtes ved analysen 5 b) Fremstilling af antistoffer overfor insulin.
Man ggv·' 10 marsvin &n;- ugentlig intramuskulær injektion med 1 mg grise-insulin i fuldstændig Freud's adjuvans gennem en periode på ^+-8 uger. Efter 10 ugers hvile gav man dyrene yderligere 1 mg insulin ved intravenøs injektion uden adjuvans. To uger senere blev 10 dyrene åreladt. Man modarbejdede den tilstødende hypoglycæmi ved intraperional administration af glucose.
c) Fremstilling af antistoffer ' overfor. maxsvin-γ-globulin.
Der . fremstilledes marsvin-Y-globulin ved tilsætning af 1 15 volumen ^mættet ammoniumsulfat-opløsninq til 2 volumen marsvine- serum. Den fremkomne udskillelse vaskedes to gange med 33i° mættet ammoniumsulfat-opløsning, hvorefter den optoges i en fysiologisk saltopløsning. Derpå immuniseredes et får med voksende doser af det fremstillede γ-globulin: 0,5 - 1 og 2 mg. Injektionerne blev 20 givet hver anden uge, idet immunogenet var blandet med fuldstændig
Freud's adjuvans. To uger efter den sidste injektion gaves der yderligere 2 mg γ-globulin i en fysiologisk saltopløsning, og en uge senere blev dyret åreladt.
25 d) Fremstilling af uopløselige antistoffer overfor marsvin-Y-globulin.
10 g mikrokrystallinsk cellulose aktiveredes ved, at det under omrøring sattes til H00 ml 2,5$ w/v CWBr-opløsning, hvorefter pH-værdien øgedes til 10,5 nied 1 N NaOH-opløsning, idet denne værdi opret 30 holdtes i 2 minutter. Derpå vaskedes cellulosen med isvand og med 0,1 M NaHCOy Der tilsattes 1,6 g Na^SO^ til 10 ml fåre-anti( marsvin.-γ-globulin) -serum. Efter en times omrøring ved stuetemperatur centrifugeres udfældningen. Der vaskedes to gange med 20 ml 16$ w/v Na^O^-opløsning, hvorefter det optoges i 10 ml 0,1 M NaHCO^-35 opløsning. Den aktiverede cellulose blandedes med *+0 ml 0,1 M NåKCO^- opløsning og de 10 ml γ-globulin-opløsning. Denne suspension om-rørtes i ^0 timer ved ^°0 og vaskedes efterhånden to gange med 150690 13 500 ml 0,5 M NaHCO^j to gange med 500 ml 0,05 M citrat af pH-værdien 1,1 og to gange med 500 ml 0,05 M phosphat af pH-værdien 6?5 5 e) Bestemmelse af antistoffer overfor insulin.
0,1 ml insulin-(glucose-oxidase) inkuberedes i passende fortynding med 0,*+ ml af en fortynding s serie af en marsvin-anti-insulin-serum i timer. Fortynding s s er i en foretoges med 0,05 M phosphat-stødpude med pH-værdien 6,0. Derpå tilsattes 0,3 ml immunoadsorbent 10 (15 mg/ml) og 0,2 ml stødpude, og blandingen omrørtes natten over ved *f°C. Efter centrifugering bestemtes enzymaktiviteten'af den resterende opløsning ved incubering af 0,5 ml af denne med 2,5 ml substrat i 30 minutter, hvorpå man målte ekstinetionen ved *+60 nm. Substratet indeholdt 50 mg glucose, 10 μg peroxidase og 1 mg 15 5- amino salicyl syre pr. 2,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,0.
Med dette system kunne antistofindholdet i de forskellige slags serum sammenlignes. Som referencepunkt valgtes den serumfortynding, hvor 5o5 af den totale kombinerbare enzymaktivitet er bundet.
20 f) Bestemmelse af insulin.
0,2 ml af en fortyndingsserie af insulin incuberedes i 2 timer med 0,1+ ml anti-insulin-serum i en sådan fortynding, at den kunne binde 60$ af det tilsatte enzym-conjugat. Derpå tilsattes 0,1 ml 25 insulin-(glucose-oxidase) · des i timer. Endelig tilsattes 0,3 ml immunoadsorbent (15 mg/ml). Blandingen omrørtes natten over ved H°C. Efter centrifugering måltes enzymaktiviteten i resto. løsningen som angivet under e). Bestemmelsens følsomhed, som afhænger af det anvendte antiserum, lig-30 ger indenfor nanogram-ordenen: 20-100 mg/ml, d.v.s* 0,5-2,5 mU/ml.
Eksempel III.
Bestemmelse af oestradiol.
35 a) Fremstilling af oestradiol-17-succinyl-HRP.
50 mg oestradiol-17-hemisuceinat og 0,08 ml tri-n-butylamin opløstes i 2,5 ml dioxan. Til den kolde (2°C) opløsning sattes 15 Hl isobutylchlorocarbonat. Efter 3o minutter blandedes denne opløsning
lif T5069Q
med 100 mg peberrodsperoxidase (HRP) i 7?5 ml af en dioxan/vand-blanding (2:3)5 som var indstillet til en pH-værdi på 9j5 med natriumhydroxid. Opløsningen omrørtes i *+ timer ved 2°C og dialyseredes derpå i 18 timer. Udfældningen, der var dannet efter at dialysatets 5 pH-værdi var indstillet til *+,6, centrifugeredes fra, vaskedes og op toges i 5 ml destilleret vand, som var indstillet til en pH-værdi på 8. Stoffet rensedes yderligere ved to ganges udfældning med 10 ml acetone. Det færdige produkt optoges i 10 ml 0,05 M piiospliat-stødpude med pH-værdien 738.
10 b) Fremstilling af østradiol-17-suecinyl-BSA.
Fremstillingen foretoges ifølge den blandede anhydrid-metode, som er angivet i eksempel Illa. Denne fremstilling foretoges, idet man gik ud fra 100 mg østradiol-17-hemisuccinat og 150 mg hornkvægsse-15 rum-albumin (BSA).
c) Fremstilling af antistoffer overfor østradiol.
Man injicerede et får en gang i *+ uger med k mg østradiol-17-succinyl-BSA i fuldstændig Freund's adjuvans. Med regelmæssige mellem 20 rum udtoges der blod fra dyret. Serumet absorberedes med BSA, som var gjort uopløseligt.
d) Fremstilling af antistoffer overfor fåre-Y-globulin.
Der fremstilledes fåre-Y-globulin som angivet i eksempel I, men nu 25 med 16$ w/v natriumsulfat. Man immunicerede så kaniner med denne fåre-Y-globulin efter følgende skema:
Dag mængde Freund's ad.iuvans innektionsmåde 0 200 ^g + intramuskulær 30 lb *+00 μg + ' " 28 800 μg + " b2 800 ug - intravenøs o c 2 Uger efter den sidste injektion blev dyret åreladt.
i5 150690 e) Fremstilling af immunoadsorbenten /kanin-anti (-fåre-Y-globulin)_7-cellulose.
Y-Globulinfraktionen fra de antisera, der er angivet under d), fremstilledes ved udfældning med 18$ w/v Wa^SO^. Det fremkomne produkt 5 kobledes med cellulose efter Gurvich's metode, angivet i eksempel I.
f) Bestemmelse af østradiol.
Immunreaktionen udførtes i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ BSA.
10 5 ml af prøven blandedes med 0,1 ml af fåre-anti-østradiolserumet i den ønskede fortynding. Efter 30 minutters inkubation ved stuetemperatur tilsattes 0,1 ml østradiol-17-succinyl-HRP i en passende fortynding, hvorefter der fulgte en anden 30 minutters inkubation 15 ved stuetemperatur. Derpå tilsattes Qf3 ml immunoadsorbent"su" spension (30 mg/mll, og blandingen omrørtes i 2 timer ved stue" temperatur. Derpå adskiltes den flydende og den faste fase ved centrifugering. Enzymaktiviteten i den flydende bestanddel måltes som angivet i eksempel I. Man kunne anvende fåre-anti-østradiol-20 serumet i fortyndinger fra 1:1600 til 1:12800 i afhængighed af kva liteten af det anvendte østradiol-17-succinyl-HRP. Ved en fortynding af 1:12800 af antiserumet kunne en østradiol-koncentration på 10 ng/ml opdages i prøven. Østradiol og østron viste en krydsreaktion i dette system.
25
Eksempel IV
Bestemmelse af cortisol og corticoid-bindende globulin.
a) Fremstilling af cortisol-21-(galaktose-oxidase).
30 Man koblede 50 mg cortisol-21-hemisuccinat og 100 mg galaktose- oxidase ved hjælp af den blandede anhydrid-teknik angivet i eksempel Illa.
b) Corticoid-bindende globulin (CBG) isoleredes fra human serum ved 35 hjælp af successions-kromatografi over DEAE-cellulose og hydroxyl- apatit.
Antistoffer overfor dette fremstilledes ved injicering af kaniner i 1^—dagesmellemrum med 500 Pg CBG i fuldstændig Freund's adjuvans.
Efter 3 måneder injiceredes dyrene med 1 mg CBG, og 2 uger senere i6 150690 c) γ-Globulin- fraktionen af anti-CBG- serum koblede s til m- aminobenzy1= oxymethylcellulose som angivet i eksempel III.
d) Bestemmelse af cortisol.
5 0,5 nil af en prøve, der indeholdt cortisol (standard-opløsning) ekstraheredes med 2 x 3 nil methylenchlorid. Den sammenbragte ekstraktionsvæske inddampedes til tørhed. Residuenten optoges i 0,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Derpå blandedes med 0,1 ml af en opløsning af CBG i den samme stødpude i en passende 10 koncentration, og der inkuberedes i 30 minutter ved h°C. Derpå tilsattes 0,1 ml cortisol-21-(galaktose-oxidase), også i passende fortyndingjOg 0,3 ml af immunoadsorbenten, der fremstilledes under c), med en koncentration af 5 mg/ml. Den fremkomne blanding omrør-tes i 2 timer ved ^°0 og derpå centrifugeredes, hvorefter enzymakti-15 viteten måltes i restvæsken. I den anledning tilsattes 0,5 nil af samme til 1,5 ml substrat bestående af 100 mg D-galaktose, 20 mg 5-aminosalicylsyre og 10 Mg peroxidase i 150 ml 0,02 M phosphat-stødpude med pH-værdien 6,0. Efter 30 minutter måltes ekstinctionen ved *+60 nm. Ved anvendelse af en CBG-koncentration på O,1* Mg/ml og 20 'så meget cortisol-21-(galaktose-oxidase), at 80$ af enzym-konjugatet var bundet til immunoadsorbenten, uden at der tilføjedes steroider, viste det sig muligt at bestemme mængder af fra 3 til 30 ng cortisol e) Bestemmelse af CBG var også mulig med de angivne reagenser. Fra en 25 fortyndingsserie af transcortin, rækkende fra O til 1280 ng/ml in kuberedes 0,5 ml i 15 minutter med 0,2 ml cortisol-21-(galaktose-oxidase) i passende fortynding. Derpå tilsattes 0,3 ml immunoad-sorbent-suspension (5 mg/ml), og blandingen omrørtes i 15 minutter. De to inkubationer holdtes ved Η-°ϋ. Derpå måltes enzymaktiviteten 30 i restvæsken som under d) c Analysemetodens følsomhed viste sig at være 50 ng/ml).
Eksempel V
35 I en flaske lyofiliseredes efterhånden følgende reagenser i adskilte lag: 0,3 ml af immunoadsorbent-suspensionen (10 mg/ml) som angivet i eksempel la.
40 2) 0,1 ml af en Ifo mannitol-opløsning.
Claims (2)
1. Fremgangsmåde til bestemmelse af en komponent i reaktionen 2Q mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et kob'lingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det specifikke binderyprotein 25 (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), kendetegnet ved, at man yderligere anvender uopløseliggiorte antistoffer over for det specifikke binder-protein, og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller den faste fase af 3Q reaktionsblandingen. 1
2 Fremgangsmåde ifølge krav 1, kendetegnet ved, at man tilsætter de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens. 35 2 Fremgangsmåde ifølge krav 2 til bestemmelse af det bindelige stof, kendetegnet ved, at man først til prøven sætter det specifikke binder-protein og derpå enzymconjugatet og til sidst de uopløselige antistoffer over for det specifikke binder-
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7018838 | 1970-12-28 | ||
| NL707018838A NL154599B (nl) | 1970-12-28 | 1970-12-28 | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK150690B true DK150690B (da) | 1987-05-25 |
| DK150690C DK150690C (da) | 1988-06-06 |
Family
ID=19811894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK639871A DK150690C (da) | 1970-12-28 | 1971-12-28 | Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof ved enzym-immunoanalyse |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US3839153A (da) |
| JP (3) | JPS5834783B1 (da) |
| AT (1) | AT320145B (da) |
| AU (1) | AU467394B2 (da) |
| BE (1) | BE777309A (da) |
| BR (1) | BR7108553D0 (da) |
| CA (1) | CA964560A (da) |
| CH (1) | CH557030A (da) |
| DE (1) | DE2164768B2 (da) |
| DK (1) | DK150690C (da) |
| EG (1) | EG11604A (da) |
| ES (1) | ES398372A1 (da) |
| FI (1) | FI54034C (da) |
| FR (1) | FR2120835A5 (da) |
| GB (1) | GB1348938A (da) |
| IL (1) | IL38371A (da) |
| IT (1) | IT965020B (da) |
| NL (1) | NL154599B (da) |
| SE (1) | SE398557B (da) |
| ZA (1) | ZA718332B (da) |
Families Citing this family (884)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE31006E (en) * | 1968-09-24 | 1982-08-03 | Akzona Incorporated | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
| NL171930C (nl) * | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3790447A (en) * | 1972-07-05 | 1974-02-05 | Abbott Lab | Streptococci diagnostic method |
| US4239746A (en) * | 1973-06-30 | 1980-12-16 | Dezso Istvan Bartos | Complement fixation test employing reactants in a disposable package |
| DE2333434C3 (de) * | 1973-06-30 | 1978-04-06 | Istvan D. Dr. 5024 Pulheim Bartos | Verfahren zur Durchführung serologischer Untersuchungen nach dem Prinzip der Komplementbindungsreaktion und gebrauchsfertige Schnelltestpackung hierfür |
| US3935074A (en) * | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| GB1508132A (en) * | 1974-05-20 | 1978-04-19 | Technicon Instr | Analysis of biological fluids |
| US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
| US4001087A (en) * | 1974-10-10 | 1977-01-04 | The United States Of America | Affinity labelling enzymes with esters of aromatic sulfonic acids |
| FR2288312A1 (fr) * | 1974-10-14 | 1976-05-14 | Pasteur Institut | Procede de dosage immunoenzymatique de la progesterone |
| US4002532A (en) * | 1974-10-21 | 1977-01-11 | Weltman Joel K | Enzyme conjugates |
| SE388694B (sv) * | 1975-01-27 | 1976-10-11 | Kabi Ab | Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar |
| NL7501215A (nl) * | 1975-02-01 | 1976-08-03 | Akzo Nv | Methode voor het aantonen en bepalen van een antigeen of antilichaam. |
| US4629688A (en) * | 1975-04-28 | 1986-12-16 | Miles Laboratories, Inc. | Homogeneous specific binding assay method |
| US4230797A (en) * | 1975-04-28 | 1980-10-28 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a coenzyme as label |
| USRE32696E (en) * | 1975-09-04 | 1988-06-14 | Akzona Incorporated | Enzymatic immunological method for determination of antigens and antibodies |
| US4474878A (en) * | 1975-09-29 | 1984-10-02 | Cordis Laboratories, Inc. | Sandwich EIA for antigen associated with hepatitis |
| US4642285A (en) * | 1975-09-29 | 1987-02-10 | Diamedix Corporation | Sandwich EIA for antigen |
| SE7610683L (sv) * | 1975-09-29 | 1977-06-10 | Cordis Corp | Metod for bestemning av nervaron av ett antigen associerat med hepatit |
| JPS5272284A (en) * | 1975-12-12 | 1977-06-16 | Dainippon Pharmaceutical Co | Enzymeeimmunoassay reagent |
| US4045384A (en) * | 1976-07-23 | 1977-08-30 | The Dow Chemical Company | Method for forming an amide bond between a latex and protein |
| GB1549069A (en) * | 1976-12-10 | 1979-08-01 | Erba Farmitalia | Enzyme linked immunoassay |
| US4200690A (en) * | 1976-12-16 | 1980-04-29 | Millipore Corporation | Immunoassay with membrane immobilized antibody |
| US4407943A (en) * | 1976-12-16 | 1983-10-04 | Millipore Corporation | Immobilized antibody or antigen for immunoassay |
| JPS5399319A (en) * | 1977-02-09 | 1978-08-30 | Hidematsu Hirai | Novel qualitative and quantitative detecting method and detecting body for antgenic substance |
| IT1114861B (it) * | 1977-05-12 | 1986-01-27 | Sclavo Inst Sieroterapeut | Metodo per la determinazione del contenuto di costituenti di fluidi biologici e mezzi adatti allo scopo |
| AU531777B2 (en) * | 1978-04-05 | 1983-09-08 | Syva Co. | Label/solid conjugate immunoassay system |
| US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| US4492751A (en) * | 1978-04-10 | 1985-01-08 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing an enzyme substrate as label |
| US4318980A (en) * | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| FR2422956A1 (fr) * | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
| US5605800A (en) * | 1978-04-13 | 1997-02-25 | Institut Pasteur | Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method |
| JPS5510590A (en) * | 1978-05-04 | 1980-01-25 | Wellcome Found | Enzyme immunity quantity analysis |
| JPS5539702A (en) * | 1978-08-30 | 1980-03-19 | Takeda Chem Ind Ltd | Method of measuring enzyme immunity of pancreas glucagon |
| FR2440555A1 (fr) * | 1978-10-31 | 1980-05-30 | Maes Roland | Perfectionnements aux procedes de determination de substances montrant entre elles des affinites de liaison specifiques, par des tests faisant intervenir une phase solide |
| US4260678A (en) * | 1979-02-23 | 1981-04-07 | Corning Glass Works | Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes |
| JPS55152459A (en) * | 1979-05-18 | 1980-11-27 | Yamasa Shoyu Co Ltd | Method and reagent for measuring quantity of cyclic nucleotide |
| US4289748A (en) * | 1979-05-31 | 1981-09-15 | United States Of America | Ultrasensitive enzymatic radioimmunoassay method |
| DE2930706A1 (de) * | 1979-07-28 | 1981-02-05 | Medac Klinische Spezialpraep | Verfahren zum nachweis von erregerspezifischen antikoerpern |
| US4299916A (en) * | 1979-12-26 | 1981-11-10 | Syva Company | Preferential signal production on a surface in immunoassays |
| US4394391A (en) * | 1980-02-19 | 1983-07-19 | Thorell Jan Ivan | Radioimmunoassay reagents |
| US4322495A (en) * | 1980-03-11 | 1982-03-30 | Minnesota Mining And Manufacturing Co. | Immunoassay |
| EP0040728A1 (en) * | 1980-05-19 | 1981-12-02 | Pharmacia Diagnostics Ab | An improvement in and relating to assaying methods involving biospecific affinity reactions |
| SE8003732L (sv) * | 1980-05-19 | 1981-11-20 | Pharmacia Diagnostics Ab | Sett vid bestemningsmetoder involverande biospecifika affinitetsreaktioner |
| JPS5714748A (en) * | 1980-07-01 | 1982-01-26 | Dainippon Pharmaceut Co Ltd | Kit for quantitative determination of valproic acid and its method for quantitative determination |
| US4323647A (en) * | 1980-10-15 | 1982-04-06 | University Of Miami | Steric hindrance enzyme immunoassay |
| DE3048884A1 (de) * | 1980-12-23 | 1982-07-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur enzymimmunobestimmung in heterogener phase |
| ES8307897A1 (es) * | 1981-04-13 | 1983-08-01 | Hoechst Co American | Un metodo de determinar la presencia de un antigeno en un medio liquido sospechoso de contenerlo. |
| US4604365A (en) * | 1981-06-02 | 1986-08-05 | Electro-Nucleonics, Inc. | Immunoprecipitation assay |
| WO1982004323A1 (en) * | 1981-06-02 | 1982-12-09 | O Neill Sean | Immunoprecipitation assay |
| US4506009A (en) * | 1982-03-30 | 1985-03-19 | University Of California | Heterogeneous immunoassay method |
| US4535057A (en) * | 1982-07-26 | 1985-08-13 | Amf Incorporated | Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system |
| US4515890A (en) * | 1982-11-08 | 1985-05-07 | Abbott Laboratories | Immunoassay of terminal deoxynucleotidyl transferase |
| US4650751A (en) * | 1983-04-29 | 1987-03-17 | Technicon Instruments Corporation | Protected binding assay avoiding non-specific protein interference |
| US4778752A (en) * | 1983-10-11 | 1988-10-18 | Scripps Clinic And Research Foundation | Receptors specific for hapten-modified self proteins |
| US4937199A (en) * | 1985-03-18 | 1990-06-26 | The Royal Free Hospital School Of Medicine | Detection of viruses and antibodies |
| JPS62148857A (ja) * | 1985-12-24 | 1987-07-02 | Toyo Soda Mfg Co Ltd | 免疫測定用材料の製造方法 |
| EP0247730A3 (en) * | 1986-04-28 | 1989-04-12 | Antibody Technology Limited | Antibodies, their preparation and use and products containing them |
| DE3636724A1 (de) * | 1986-10-29 | 1988-06-23 | Joern Dr Med Kekow | Enzymimmunoassay (elisa) zur insulinbestimmung im mikrotiterplattensystem |
| US6528292B1 (en) * | 1987-05-29 | 2003-03-04 | Aventis Pharmaceuticals Holdings Inc. | Derivatized polystyrene and other polymer supports for spectroscopic studies |
| US5256372A (en) * | 1987-11-06 | 1993-10-26 | Idexx Corporation | Dipstick test device including a removable filter assembly |
| US5137804A (en) * | 1988-05-10 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Assay device and immunoassay |
| US5374524A (en) * | 1988-05-10 | 1994-12-20 | E. I. Du Pont De Nemours And Company | Solution sandwich hybridization, capture and detection of amplified nucleic acids |
| US5614504A (en) * | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
| CA2113823A1 (en) * | 1991-07-19 | 1993-02-04 | Cytimmune Sciences, Inc. | Method and kit for measuring endogenous cytokines |
| US5965379A (en) * | 1991-07-19 | 1999-10-12 | Cytimmune Sciences Inc. | Method for measuring endogenous cytokines |
| US5464749A (en) | 1991-07-22 | 1995-11-07 | Bayer Corporation | Immunoassay of free substances in biological fluids |
| US5874423A (en) * | 1992-09-10 | 1999-02-23 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Digitalis-like compounds |
| US5637467A (en) * | 1992-10-13 | 1997-06-10 | Behringwerke Ag | Heterogeneous assay using a pendulous drop |
| AU2635295A (en) * | 1994-06-13 | 1996-01-05 | Henry Ford Health System | A novel neuronal-neonatal gene: neuronatin |
| US5843673A (en) * | 1994-10-25 | 1998-12-01 | Curators Of The University Of Missouri | Method of screening for endometriosis |
| US6531277B2 (en) | 1994-10-25 | 2003-03-11 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
| US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
| US5607565A (en) * | 1995-03-27 | 1997-03-04 | Coulter Corporation | Apparatus for measuring analytes in a fluid sample |
| US5777093A (en) * | 1995-05-16 | 1998-07-07 | Ramot-University Authority For Applied Research & Industrial Development Ltd. | cDNAs associated with ataxia-telangiectasia |
| US5728807A (en) * | 1995-05-16 | 1998-03-17 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Mutated proteins associated with ataxia-telangiectasia |
| US5858661A (en) | 1995-05-16 | 1999-01-12 | Ramot-University Authority For Applied Research And Industrial Development | Ataxia-telangiectasia gene and its genomic organization |
| US6096508A (en) * | 1995-08-16 | 2000-08-01 | Kirkegaard & Perry Laboratoies, Inc. | Method of reducing background in biotin-based assays |
| US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
| DE69829857T2 (de) * | 1997-08-21 | 2006-02-02 | Quark Biotech, Inc., Pleasanton | Hypoxie-regulierte gene |
| US7973156B2 (en) | 1997-08-21 | 2011-07-05 | Quark Pharmaceuticals Inc. | Hypoxia-regulated genes |
| US6284496B1 (en) | 1997-10-03 | 2001-09-04 | University Of South Florida | DNA vector for determining the presence of out-of-reading-frame mutations |
| AU748467B2 (en) | 1997-10-17 | 2002-06-06 | University Of South Florida | Method to diagnose and monitor cellular immune deficiencies |
| US7687057B2 (en) | 1998-01-09 | 2010-03-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs, and uses related thereto |
| US20080206206A1 (en) | 1998-05-07 | 2008-08-28 | University Of South Florida | Bone marrow-derived neuronal cells |
| US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
| US7605149B1 (en) | 1998-07-13 | 2009-10-20 | University Of South Florida | Modulation of the phospholipase A2 pathway as a therapeutic |
| US6187563B1 (en) | 1998-08-07 | 2001-02-13 | Yale University | βIV-spectrin-polypeptides and nucleic acids encoding same |
| JP2003523166A (ja) | 1998-09-29 | 2003-08-05 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
| BR0009403A (pt) | 1999-02-04 | 2001-11-27 | Technion Res & Dev Foundation | Método de expansão/conservação das células detronco hemopoiéticas indiferenciadas ou dascélulas progenitoras, método de preparação deum meio condicionado de célula estomacal útil naexpansão/conservação das células de troncohemopoiéticas indiferenciadas ou das célulasprogenitoras, método de transplante de célulasde tronco hemopoiéticas indiferenciadas ou decélulas progenitoras em um recipiente, tampão debiorreator e biorreator |
| US6440682B1 (en) * | 1999-05-28 | 2002-08-27 | Detroit R&D Inc. | Detection of hypertension using immunoreactive metabolic products |
| US6787318B1 (en) * | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
| US7534605B2 (en) | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
| CA2377541A1 (en) * | 1999-06-25 | 2001-01-04 | Eduardo N. Mitrani | Method of inducing angiogenesis by micro-organs |
| US6875582B1 (en) | 1999-08-19 | 2005-04-05 | Omniscience Pharmaceuticals, Inc. | Methods and targets of antibiotic resistance |
| US7101839B1 (en) | 1999-08-30 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
| US7223902B1 (en) * | 1999-11-19 | 2007-05-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant |
| US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
| WO2001053323A2 (en) * | 2000-01-24 | 2001-07-26 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby |
| DE60142475D1 (de) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| IL135884A (en) * | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
| HUP0300810A2 (hu) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
| US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| DK2359854T3 (da) | 2000-08-08 | 2013-11-04 | Technion Res & Dev Foundation | Farmaceutiske sammensætninger og fremgangsmåder egnet til modulering af angiogenese |
| EP1683874A3 (en) | 2000-08-29 | 2006-10-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents |
| US7632522B2 (en) * | 2000-09-28 | 2009-12-15 | Nanocyte Inc. | Use of stinging cells/capsules for the delivery of active agents to keratinous substances |
| US20070281037A9 (en) * | 2000-09-28 | 2007-12-06 | Nanocyte Inc. | Sterile preparations and compositions including stinging capsules and methods of producing and using same |
| AU2001295850A1 (en) * | 2000-09-28 | 2002-04-08 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| ES2425321T3 (es) | 2000-11-17 | 2013-10-14 | Vascular Biogenics Ltd. | Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU1846102A (en) | 2000-11-24 | 2002-06-03 | Cardimmune Ltd | Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis |
| US20040106120A1 (en) | 2000-11-30 | 2004-06-03 | Rachid Tazi-Ahnini | Diagnosis and treatment of disease |
| EP1337152A4 (en) * | 2000-11-30 | 2004-08-11 | Yeda Res & Dev | METHODS OF USING CULTURED T CELLS THAT DO NOT INDUCE HOST Graft Reaction (GVHD) TO TREAT DISEASE |
| US20020142287A1 (en) * | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
| US7087395B1 (en) | 2001-01-16 | 2006-08-08 | Quest Diagnostics Investments Incorporated | Vitamin D assay |
| WO2002057408A2 (en) * | 2001-01-17 | 2002-07-25 | Ramot At Tel Aviv University Ltd. | Chitinases, derived from carnivorous plants polynucleotide sequences encoding thereof, and methods of isolating and using same |
| US20050202098A1 (en) | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
| AU2002230061A1 (en) * | 2001-01-31 | 2002-08-12 | Tolaren | Induction of tolerance by apoptotic and/or necrotic cells |
| US20030003454A1 (en) | 2001-03-23 | 2003-01-02 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer |
| US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
| WO2003008534A2 (en) * | 2001-07-19 | 2003-01-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof |
| CA2458640A1 (en) | 2001-08-16 | 2003-03-06 | Bar-Ilan University | Diagnosis, prevention and treatment of cancer |
| US7138144B2 (en) * | 2001-09-07 | 2006-11-21 | Nadir Askenasy | Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation |
| US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| US20060068405A1 (en) * | 2004-01-27 | 2006-03-30 | Alex Diber | Methods and systems for annotating biomolecular sequences |
| CA2463816C (en) | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| AUPR842501A0 (en) * | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| AU2002358947A1 (en) * | 2001-12-05 | 2003-06-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof |
| US20050085432A1 (en) * | 2001-12-26 | 2005-04-21 | Aviva Lapidot | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
| IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| EP1465982A4 (en) | 2002-01-25 | 2006-06-07 | Gamida Cell Ltd | PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED |
| US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
| US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) * | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| WO2003078567A2 (en) * | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
| ATE394125T1 (de) * | 2002-03-26 | 2008-05-15 | Nanocyte Inc | Nesselzellen mit expression eines exogenen polynucleotids, das ein therapeutisches, diagnostisches oder kosmetisches mittel kodiert, und diese nesselzellen verwendende verfahren, zusammensetzungen und vorrichtungen oder daraus gewonnene kapseln zur abgabe des therapeutischen, diagnostischen oder kosmetischen mittels in ein gewebe |
| US20040121442A1 (en) * | 2002-05-05 | 2004-06-24 | Ilan Chet | Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof |
| AU2003242967A1 (en) * | 2002-07-12 | 2004-02-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method and device for inducing biological processes by micro-organs |
| EP2561889A3 (en) | 2002-08-01 | 2013-04-03 | Yeda Research and Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| US7267981B2 (en) | 2002-10-07 | 2007-09-11 | Technion Research & Development Foundation Ltd. | Human foreskin fibroblasts for culturing ES cells |
| US20040146949A1 (en) * | 2002-10-25 | 2004-07-29 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease |
| EP2295980A1 (en) | 2002-10-30 | 2011-03-16 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Molecules and methods using same for measuring non-transferrin bound iron |
| US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
| WO2004050826A2 (en) * | 2002-11-29 | 2004-06-17 | Technion Research & Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
| US7491699B2 (en) * | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| WO2004052275A2 (en) | 2002-12-12 | 2004-06-24 | R.B.T. (Rakuto Bio Technologies) Ltd. | Methods of producing lignin peroxidase and its use in skin and hair lightening |
| ES2705683T3 (es) | 2002-12-16 | 2019-03-26 | Technion Res & Dev Foundation | Medio de cultivo de células madre pluripotentes |
| JP2006512079A (ja) | 2003-01-02 | 2006-04-13 | ラッパポート・ファミリー・インスティチュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシズ | 高血糖性患者の心疾患を予防するための抗酸化治療の有効性を予測する方法 |
| ATE426575T1 (de) * | 2003-01-07 | 2009-04-15 | Univ Ramot | Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben |
| US7786071B2 (en) | 2003-03-04 | 2010-08-31 | Yeda Research And Development Co. Ltd. | Pon polypeptides polynucleotides encoding same and compositions and methods utilizing same |
| US20050054103A1 (en) * | 2003-03-07 | 2005-03-10 | Tony Peled | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
| US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
| US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
| ES2433440T3 (es) | 2003-04-04 | 2013-12-11 | Yeda Research And Development Co. Ltd. | Anticuerpos contra MMP2 o MMP9 y composiciones farmacéuticas que contienen los mismos útiles para inhibir la actividad de dichas metaloproteínas |
| US8252588B2 (en) | 2003-04-08 | 2012-08-28 | Yeda Research And Development Co. Ltd. | Stem cells having increased sensitivity to SDF-1 and methods of generating and using same |
| FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
| US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
| AU2005234725B2 (en) | 2003-05-22 | 2012-02-23 | Evogene Ltd. | Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby |
| CA2978152C (en) | 2003-05-22 | 2021-01-26 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby |
| US7554007B2 (en) | 2003-05-22 | 2009-06-30 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants |
| US20050020499A1 (en) * | 2003-05-27 | 2005-01-27 | Bar Ilan University | Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method |
| US8129514B2 (en) * | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
| US7498428B2 (en) * | 2003-06-19 | 2009-03-03 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
| JP5137400B2 (ja) | 2003-06-30 | 2013-02-06 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
| CN101076585A (zh) * | 2003-08-14 | 2007-11-21 | 生物平衡公司 | 细菌株系、包括该细菌株系的组合物和其益生菌用途 |
| WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
| DK1678209T3 (da) | 2003-10-07 | 2011-06-27 | Yeda Res & Dev | Antistoffer mod nik, deres frembringelse samt anvendelse |
| EP1678294A1 (en) * | 2003-10-23 | 2006-07-12 | Pfizer Products Inc. | Vaccine for periodontal disease |
| JP5039383B2 (ja) | 2003-11-30 | 2012-10-03 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 免疫モジュレーションのための方法および薬剤ならびに免疫モジュレーターの同定方法 |
| WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
| US20100221233A1 (en) * | 2003-12-15 | 2010-09-02 | University Of South Florida | Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
| EP2289567A3 (en) | 2003-12-22 | 2011-06-22 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring crosslinked protein backbone |
| US8007847B2 (en) | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
| US7423139B2 (en) * | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
| EP1729793B1 (en) | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
| CA2570195C (en) | 2004-06-14 | 2017-10-24 | Evogene Ltd. | Polynucleotides and polypeptides involved in plant fiber development and methods of using same |
| US8962915B2 (en) | 2004-06-14 | 2015-02-24 | Evogene Ltd. | Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same |
| US8680062B2 (en) * | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
| WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
| EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS |
| US20060095241A1 (en) * | 2004-10-29 | 2006-05-04 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US8000900B2 (en) | 2004-09-21 | 2011-08-16 | Microsoft Corporation | Association-based predictions of pathogen characteristics |
| EP1805319B1 (en) * | 2004-09-29 | 2014-09-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Recombinant human t2 rnase and uses thereof |
| DE602005023332D1 (de) | 2004-09-29 | 2010-10-14 | Collplant Ltd | Kollagenproduzierende pflanzen sowie verfahren zu deren erzeugung und verwendung |
| EP1809374A4 (en) * | 2004-10-12 | 2008-09-10 | Closed Loop Therapies Ltd | IMPLANTABLE METHODS AND DEVICES FOR TREATING SUPRAVENTRICULAR ARRHYTHMIAS |
| US8478535B2 (en) | 2004-10-29 | 2013-07-02 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US20060134680A1 (en) * | 2004-12-22 | 2006-06-22 | Alexander Kotlyar | Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof |
| US20080082678A1 (en) * | 2005-01-16 | 2008-04-03 | Zlango Ltd. | Communications Network System and Methods for Using Same |
| JP2008527563A (ja) | 2005-01-16 | 2008-07-24 | ズランゴー リミテッド | アイコニック通信 |
| WO2007080558A2 (en) * | 2006-01-16 | 2007-07-19 | Zlango Ltd. | Communications network system and methods for using same |
| DK1843850T3 (da) | 2005-01-31 | 2015-12-07 | Realbio Technologies Ltd | Kapillaranordning med lateral strømning til flertrinsreaktion |
| EP2316441A1 (en) | 2005-02-17 | 2011-05-04 | Hadasit Medical Research Services And Development | Bisphosphonates for treating endometriosis |
| JP5432455B2 (ja) | 2005-02-25 | 2014-03-05 | ザ ステート オブ イスラエル、ミニストリー オブ アグリカルチャー アンド ルーラル ディベロップメント、アグリカルチュラル リサーチ オーガナイゼイション、(エー.アール.オー.)、ボルカニ センター | 炎症治療用の果実細胞培養抽出物 |
| US7695927B2 (en) * | 2005-03-18 | 2010-04-13 | Detroit R & D | Detection of hypertension using glucuronidated metabolic products |
| WO2006109312A2 (en) * | 2005-04-15 | 2006-10-19 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease |
| US8834862B2 (en) * | 2005-04-19 | 2014-09-16 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent |
| CA2606018A1 (en) * | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Nanoparticle conjugates |
| US20060246523A1 (en) | 2005-04-28 | 2006-11-02 | Christopher Bieniarz | Antibody conjugates |
| EP1888034A2 (en) | 2005-05-26 | 2008-02-20 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
| EP1893747B1 (en) | 2005-06-16 | 2014-09-03 | Ramot at Tel Aviv University Ltd. | Isolated cells and populations comprising same for the treatment of cns diseases |
| US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
| WO2007007317A1 (en) | 2005-07-07 | 2007-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
| WO2007007325A2 (en) | 2005-07-07 | 2007-01-18 | Fulcrum Sp Ltd. | Sp1 polypeptides, modified sp1 polypeptides and uses thereof |
| BRPI0616012A2 (pt) | 2005-07-18 | 2011-05-31 | Protalix Ltd | administração via mucosa ou intestino de macromoléculas biologicamente ativas |
| EP2889041A1 (en) | 2005-07-26 | 2015-07-01 | Rutgers, The State University of New Jersey | Kit of reagents for tuberculosis assay |
| CA2615460A1 (en) * | 2005-08-08 | 2007-02-15 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| EP1928479B1 (en) | 2005-08-24 | 2016-06-08 | Yeda Research And Development Co., Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
| WO2007026353A2 (en) | 2005-08-29 | 2007-03-08 | Technion Research & Development Foundation Ltd. | Media for culturing stem cells |
| WO2007034487A1 (en) | 2005-09-22 | 2007-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
| US20070087437A1 (en) * | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
| WO2007057967A1 (ja) * | 2005-11-18 | 2007-05-24 | Mitsubishi Denki Kabushiki Kaisha | エレベータのかご照明装置 |
| DK2963011T3 (da) * | 2005-11-23 | 2018-08-06 | Ventana Med Syst Inc | Molekylært konjugat |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| JP5102773B2 (ja) | 2005-11-29 | 2012-12-19 | ガミダ セル リミテッド | 幹細胞のホーミングおよび生着を改善する方法 |
| US20070134739A1 (en) * | 2005-12-12 | 2007-06-14 | Gyros Patent Ab | Microfluidic assays and microfluidic devices |
| EP2237037A1 (en) | 2005-12-12 | 2010-10-06 | Gyros Patent Ab | Microfluidic device and use thereof |
| US8775526B2 (en) | 2006-01-16 | 2014-07-08 | Zlango Ltd. | Iconic communication |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| CN101416063A (zh) | 2006-02-06 | 2009-04-22 | 拉帕波特家族医学科学研究所 | 用于诊断t1dm的方法和试剂盒 |
| CA2641954C (en) | 2006-03-06 | 2016-04-26 | Zetiq Technologies Ltd. | Methods and compositions for identifying a cell phenotype |
| EP2548951B1 (en) | 2006-03-23 | 2016-05-04 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
| EP2004858A4 (en) | 2006-03-28 | 2009-12-09 | Tel Hashomer Medical Res Infrastructure & Services Ltd | METHOD AND KITS FOR DETERMINING AN INVESTMENT TO WARFARINE RESISTANCE |
| KR20090029184A (ko) * | 2006-04-07 | 2009-03-20 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항체 조성물 및 신생물성 질병의 치료 방법 |
| US7977457B2 (en) * | 2006-05-19 | 2011-07-12 | Teva Pharmaceutical Industries Ltd. | Fusion proteins, uses thereof and processes for producing same |
| US20070281883A1 (en) * | 2006-06-05 | 2007-12-06 | Hanna Rosenfeld | Development of follicle stimulating hormone agonists and antagonists in fish |
| EP2046109A4 (en) | 2006-07-20 | 2010-01-06 | Yeda Res & Dev | PHOTOSYNTHETIC ORGANISMS, COMPOSITIONS AND METHODS FOR GENERATING THESE ORGANISMS |
| US8809052B2 (en) | 2006-08-28 | 2014-08-19 | Yeda Research And Development Co. Ltd. | Methods of generating mature oligodendrocytes |
| CA2664972C (en) | 2006-10-05 | 2016-07-26 | Technion Research & Development Foundation Ltd. | Microtubes and methods of producing same |
| US7888059B2 (en) * | 2006-10-05 | 2011-02-15 | Yeda Research And Development Co. Ltd. | Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same |
| EP2096909A4 (en) | 2006-12-20 | 2010-08-04 | Evogene Ltd | POLYNUCLEOTIDES AND POLYPEPTIDES INVOLVED IN THE DEVELOPMENT OF VEGETABLE FIBERS AND METHODS OF USE |
| US20100086526A1 (en) * | 2007-01-16 | 2010-04-08 | Abraham Hochberg | Nucleic acid constructs and methods for specific silencing of h19 |
| WO2008093331A1 (en) * | 2007-01-29 | 2008-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antibody conjugates for circumventing multi-drug resistance |
| WO2008093341A2 (en) | 2007-01-31 | 2008-08-07 | Technion Research & Development Foundation Ltd. | Electrospun scaffolds and methods of generating and using same |
| US8546333B2 (en) | 2007-02-01 | 2013-10-01 | Technion Research & Development Foundation Limited | Albumin fibers and fabrics and methods of generating and using same |
| ES2662036T3 (es) | 2007-02-28 | 2018-04-05 | Yeda Research And Development Company Limited | Secuencias que se dirigen al núcleo |
| CA2682093A1 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| JP2010523104A (ja) | 2007-04-02 | 2010-07-15 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | ガン細胞検出方法ならびにガン疾患の診断およびガン疾患の処置のモニタリングのためのその使用 |
| CN101854798B (zh) | 2007-04-09 | 2013-04-03 | 伊沃基因有限公司 | 用于增加植物的油含量、生长速率和/或产量的多核苷酸、多肽和方法 |
| US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
| PT2144633E (pt) * | 2007-04-23 | 2014-10-27 | Deliversir Ltd | Um sistema para a administração de agentes terapêuticos em células vivas e núcleos de células |
| US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
| US8338113B2 (en) | 2007-05-01 | 2012-12-25 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods for detecting fetal cells in the maternal blood |
| JP2010530735A (ja) | 2007-05-03 | 2010-09-16 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 細胞内のprl−1ポリペプチドまたはprl−3ポリペプチドに結合する抗体 |
| CN101861382B (zh) | 2007-05-07 | 2015-07-15 | 普罗塔里克斯有限公司 | 大规模一次性生物反应器 |
| US20100197767A1 (en) | 2007-07-11 | 2010-08-05 | Lior Nissim | Nucleic acid construct systems capable of daignosing or treating a cell state |
| JP2010533705A (ja) | 2007-07-15 | 2010-10-28 | ヒルマン,イチャク | 抗菌ペプチドまたはその阻害剤を用いた疾病治療 |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| AU2008278654B2 (en) | 2007-07-24 | 2014-06-05 | Evogene Ltd. | Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same |
| CA2693310C (en) * | 2007-08-02 | 2018-11-27 | Arresto Biosciences, Inc. | Lox and loxl2 inhibitors, antibodies and uses thereof |
| DK2185175T3 (da) | 2007-08-15 | 2013-05-13 | Yeda Res & Dev | MMP-9-regulatorer og anvendelser deraf |
| AU2008299318A1 (en) | 2007-09-12 | 2009-03-19 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating tumors in immune-privileged sites |
| KR20140107677A (ko) | 2007-09-19 | 2014-09-04 | 플루리스템 리미티드 | 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도 |
| EP2210092B1 (en) | 2007-10-19 | 2014-06-11 | Rappaport Family Institute for Research in the Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
| JP2011504374A (ja) | 2007-11-26 | 2011-02-10 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | 繊維状ポリペプチドおよび多糖を含む組成物 |
| EP2240510B1 (en) | 2007-12-27 | 2017-05-10 | Evogene Ltd. | Isolated polypeptides, polynucleotides useful for modifying salinity stress tolerance in plants |
| EP2245055A2 (en) * | 2008-01-31 | 2010-11-03 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| EP2265751B1 (en) | 2008-02-21 | 2015-04-01 | Technion Research & Development Foundation Ltd. | Method for depleting or isolating a molecule from a solution |
| US8747855B2 (en) * | 2008-04-09 | 2014-06-10 | Technion Research & Development Foundation Limited | Anti human immunodeficiency antibodies and uses thereof |
| EP2297200A1 (en) * | 2008-04-09 | 2011-03-23 | Technion Research & Development Foundation Ltd. | Anti influenza antibodies and uses thereof |
| EP2508325A3 (en) * | 2008-04-10 | 2013-05-22 | Objet Ltd. | System and method for three dimensional model printing |
| US9095569B2 (en) | 2008-04-18 | 2015-08-04 | Collplant Ltd. | Methods of generating and using procollagen |
| US8791324B2 (en) | 2008-04-21 | 2014-07-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
| JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| CA3148194A1 (en) | 2008-05-22 | 2009-11-26 | Evogene Ltd. | Isolated polynucleotides and peptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
| EP2641606A1 (en) | 2008-05-27 | 2013-09-25 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
| EP2620493B1 (en) | 2008-05-28 | 2019-03-27 | Ramot at Tel Aviv University Ltd. | Mesenchymal stem cells for the treatment of CNS diseases |
| WO2010007613A1 (en) | 2008-06-29 | 2010-01-21 | Realbio Technologies Ltd. | Liquid–transfer device particularly useful as a capturing device in a biological assay process |
| JP5583667B2 (ja) | 2008-08-08 | 2014-09-03 | ジェニスフィア・エルエルシー | 長時間作用型dnaデンドリマーおよびその方法 |
| JP5756014B2 (ja) | 2008-08-08 | 2015-07-29 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ(エイ・スター) | がんの診断および治療のためのvhz |
| WO2010020941A2 (en) | 2008-08-18 | 2010-02-25 | Evogene Ltd. | Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants |
| RU2539786C2 (ru) | 2008-09-02 | 2015-01-27 | Плуристем Лтд. | Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении |
| US8367392B2 (en) * | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
| US20110305682A1 (en) | 2008-09-11 | 2011-12-15 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and Methods for Treating S. Pneumonia Infection |
| BRPI0919020B8 (pt) | 2008-09-12 | 2021-05-25 | Cryopraxis Criobiologia Ltda | uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris |
| KR101594202B1 (ko) | 2008-09-24 | 2016-02-15 | 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드. | 세포 유착 방지를 위한 펩티드와 조성물 및 그것의 사용 방법 |
| EP2342356A4 (en) | 2008-09-29 | 2012-11-21 | Univ Ben Gurion | AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF |
| MX2011003575A (es) | 2008-10-30 | 2011-04-21 | Evogene Ltd | Polinucleotidos y polipeptidos aislados y metodos para utilizarlos para aumentar el rendimiento de la planta, biomasa, tasa de crecimiento, vigor, contenido de aceite, tolerancia al estres abiotico de las plantas y eficacia en el uso de nitrogeno. |
| WO2010055525A1 (en) | 2008-11-17 | 2010-05-20 | Technion Research & Development Foundation Ltd. | Method for predicting a patient's responsiveness to anti-folate therapy |
| WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
| WO2010061383A1 (en) | 2008-11-26 | 2010-06-03 | Biodalia Microbiological Technologies Ltd. | A method of in-situ enrichment of foods with fructan |
| WO2010064231A1 (en) | 2008-12-02 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of analyzing a-i rna editing and nucleic acid constructs capable of same |
| WO2010064247A1 (en) | 2008-12-03 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for determining predisposition to cancer |
| US8734759B2 (en) | 2008-12-05 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and treating motor neuron diseases |
| WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
| EP2376528B1 (en) | 2008-12-29 | 2014-11-26 | Tel Hashomer Medical Research, Infrastructure And Services Ltd. | Peptides and compositions for prevention of cell adhesion and methods of using same |
| EP2373792B1 (en) | 2008-12-29 | 2016-11-02 | Evogene Ltd. | Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same |
| WO2010076788A2 (en) | 2008-12-29 | 2010-07-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
| WO2010076794A1 (en) | 2008-12-31 | 2010-07-08 | Technion Research & Development Foundation Ltd. | Method of denitrifying brine and systems capable of same |
| WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
| IL196820A0 (en) | 2009-02-01 | 2009-11-18 | Yissum Res Dev Co | Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells |
| US8691760B2 (en) | 2009-02-02 | 2014-04-08 | Ramot At Tel-Aviv University | Peptides, pharmaceutical compositions comprising same and uses thereof |
| WO2010089707A1 (en) | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
| EP2401363B1 (en) | 2009-02-26 | 2018-08-22 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods of reprogramming renal cells |
| LT3460062T (lt) | 2009-03-02 | 2021-06-25 | Evogene Ltd. | Izoliuoti polinukleotidai ir polipeptidai, ir jų naudojimo būdai, skirti augalų derlingumui didinti ir (arba) žemės ūkio savybėms gerinti |
| US8546330B2 (en) | 2009-03-09 | 2013-10-01 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for treatment of neurodegenerative diseases |
| WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| WO2010113096A1 (en) | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
| US8912142B2 (en) | 2009-04-01 | 2014-12-16 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Method of regulating proliferation and differentiation of keratinocyes |
| WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
| DK2424896T3 (da) | 2009-04-30 | 2015-12-14 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Anti-CEACAM1-antistoffer og fremgangsmåder til anvendelse deraf |
| CN102576024B (zh) | 2009-05-19 | 2016-10-26 | 泽蒂克科技有限公司 | 宫颈癌细胞和/或组织的鉴别染色的试剂盒和方法 |
| EP2435072A2 (en) | 2009-05-27 | 2012-04-04 | Yeda Research and Development Co. Ltd. | Proteasome inhibitors and uses thereof |
| US20120078163A1 (en) | 2009-05-27 | 2012-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
| WO2010137013A1 (en) | 2009-05-27 | 2010-12-02 | Ramot At Tel Aviv University Ltd. | Crystallized photosystem i units from the pea plant and their use in solid state devices |
| US20120070449A1 (en) | 2009-05-28 | 2012-03-22 | Yeda Research And Development Co. Ltd. | Methods of treating inflammation |
| MX381662B (es) | 2009-06-10 | 2025-03-13 | Evogene Ltd | Polinucleotidos y polipeptidos aislados, y metodos para utilizarlos para mejorar la eficacia en el uso de nitrogeno, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o tolerancia al estres abiotico. |
| EP2446267A1 (en) | 2009-06-24 | 2012-05-02 | Health Corporation - Rambam | Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| WO2011004379A1 (en) | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
| CA2768725A1 (en) | 2009-07-21 | 2011-01-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A method of diagnosing cancer |
| GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
| WO2011021194A2 (en) | 2009-08-17 | 2011-02-24 | Technion Research & Development Foundation Ltd. | Pericyte progenitor cells and methods of generating and using same |
| EP2467396A4 (en) | 2009-08-21 | 2012-12-26 | Gilead Biologics Inc | CATALYTIC DOMAINS FROM LYSYL OXIDASE AND LOXL2 |
| US20120157512A1 (en) | 2009-08-21 | 2012-06-21 | Monsanto Technology Llc | Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules |
| WO2011022709A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vitro screening assays |
| WO2011024172A2 (en) | 2009-08-27 | 2011-03-03 | Technion Research & Development Foundation Ltd. | Liposomal compositions and uses of same |
| EP2475784A1 (en) | 2009-09-08 | 2012-07-18 | Ramot at Tel-Aviv University Ltd. | Methods of diagnosing amyotrophic lateral sclerosis (als) |
| WO2011030332A2 (en) | 2009-09-08 | 2011-03-17 | Yeda Research And Development Co. Ltd. | Methods for hematopoietic precursor mobilization |
| US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
| EP2478093A2 (en) | 2009-09-17 | 2012-07-25 | Yeda Research and Development Co. Ltd. | Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
| JP2013505230A (ja) | 2009-09-17 | 2013-02-14 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 酸化ストレス関連障害を処置するためのペプチド |
| US8735124B2 (en) | 2009-09-17 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
| US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| MX353880B (es) | 2009-10-14 | 2018-01-31 | Yissum Research Development Company Of The Hebrew Univ Of Jerusalem Ltd Star | Composiciones para controlar ácaros varroa en abejas. |
| ES2609006T3 (es) | 2009-10-16 | 2017-04-18 | Rutgers, The State University Of New Jersey | Procedimeinto de tratamiento de lesión crónica de tejido nervioso usando una estrategia de terapia celular |
| WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
| IL201999A (en) | 2009-11-08 | 2017-10-31 | Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel | A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity |
| EP2498806B1 (en) | 2009-11-12 | 2014-12-31 | Ramot at Tel-Aviv University Ltd. | Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes |
| WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
| EP3633025B1 (en) | 2009-11-12 | 2022-09-14 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
| US20120273993A1 (en) | 2009-11-24 | 2012-11-01 | Collplant Ltd. | Method of generating collagen fibers |
| CA2781649C (en) | 2009-11-30 | 2017-07-11 | Pluristem Ltd. | Adherent cells from placenta and use of same in disease treatment |
| WO2011067745A2 (en) | 2009-12-06 | 2011-06-09 | Rosetta Green Ltd. | Compositions and methods for enhancing plants resistance to abiotic stress |
| EP2510098B1 (en) | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| BR112012016033B1 (pt) | 2009-12-28 | 2021-03-09 | Evogene Ltd. | métodos de aumento de produção de semente, biomassa, taxa de crescimento, vigor, tolerância à deficiência de nitrogênio, eficiência no uso de nitrogênio e/ou redução do tempo de florescimento de uma planta, e, para produzir uma planta transgênica |
| US20130011376A1 (en) | 2009-12-29 | 2013-01-10 | Gamida Cell Ltd. | Methods for Enhancing Natural Killer Cell Proliferation and Activity |
| WO2011083464A2 (en) | 2010-01-05 | 2011-07-14 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
| SG182490A1 (en) | 2010-01-12 | 2012-08-30 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
| US8697078B2 (en) | 2010-01-27 | 2014-04-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
| US8680246B2 (en) | 2010-02-04 | 2014-03-25 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) |
| WO2011099006A2 (en) | 2010-02-11 | 2011-08-18 | Yeda Research And Development Co. Ltd. | Enzymatic systems for carbon fixation and methods of generating same |
| EP2538961B1 (en) | 2010-02-24 | 2016-10-12 | Ben Gurion University Of The Negev Research And Development Authority | Inhibition of necrosis |
| WO2011107939A1 (en) | 2010-03-01 | 2011-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting efficacy of an anti-vegfa treatment for solid tumors |
| WO2011107994A1 (en) | 2010-03-04 | 2011-09-09 | Yeda Research And Development Co. Ltd. | Methods of measuring protein stability |
| WO2011111034A1 (en) | 2010-03-08 | 2011-09-15 | Yeda Research And Development Co. Ltd. | Recombinant protein production in heterologous systems |
| ES2641642T3 (es) | 2010-03-08 | 2017-11-10 | Monsanto Technology Llc | Moléculas de polinucleótido para regulación génica en plantas |
| CN102918159A (zh) | 2010-03-11 | 2013-02-06 | 雅各布·埃德尔 | 产生氢的方法 |
| EP2556085A2 (en) | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
| WO2011128897A1 (en) | 2010-04-12 | 2011-10-20 | Technion Research & Development Foundation Ltd. | Populations of pancreatic progenitor cells and methods of isolating and using same |
| EP2557913B1 (en) | 2010-04-12 | 2016-08-03 | Ben Gurion University Of The Negev Research And Development Authority | Sulfotransferase of a red microalga and uses thereof |
| EP2561356B1 (en) | 2010-04-18 | 2016-08-03 | Yeda Research and Development Co. Ltd. | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES |
| US9328353B2 (en) | 2010-04-28 | 2016-05-03 | Evogene Ltd. | Isolated polynucleotides and polypeptides for increasing plant yield and/or agricultural characteristics |
| US20130053277A1 (en) | 2010-05-04 | 2013-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of identifying inhibitors of polypeptides-of-interest |
| US9352000B2 (en) | 2010-05-05 | 2016-05-31 | Rappaport Family Institute For Research In The Medical Sciences | Use of CCL1 in therapy |
| IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
| EP2569417B1 (en) | 2010-05-13 | 2018-04-18 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Isolated populations of adult renal cells and methods of isolating and using same |
| ES2410754T3 (es) | 2010-05-25 | 2013-07-03 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Procedimiento para la detección electroquímica de reacciones de unión |
| EP2576806B1 (en) | 2010-05-26 | 2017-03-08 | The Board of Trustees of the University of Illionis | Personal glucose meters for detection and quantification of a broad range of analytes |
| CN103037891A (zh) | 2010-06-03 | 2013-04-10 | 雷蒙特亚特特拉维夫大学有限公司 | 治疗糖尿病的方法和能够治疗糖尿病的组合物 |
| US20130316351A1 (en) | 2010-06-07 | 2013-11-28 | Osnat Ashur-Fabian | Methods and kits for diagnosing conditions related to hypoxia |
| US20130097731A1 (en) | 2010-06-16 | 2013-04-18 | Futuragene Israel Ltd. | Pest-resistant plants containing a combination of a spider toxin and a chitinase |
| EP2582842A2 (en) | 2010-06-16 | 2013-04-24 | Yissum Research Development Company of The Hebrew University of Jerusalem | Method of diagnosing and treating cancer |
| EP2593468B1 (en) | 2010-07-12 | 2020-06-10 | The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center | Isolated polynucleotides and methods and plants using same for regulating plant acidity |
| WO2012007951A1 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
| EP2593554A2 (en) | 2010-07-15 | 2013-05-22 | Technion Research And Development Foundation Ltd. | Nucleic acid construct for increasing abiotic stress tolerance in plants |
| CA2805478A1 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
| WO2012011113A2 (en) | 2010-07-22 | 2012-01-26 | Shai Yarkoni | Regulatory immune cells with enhanced targeted cell death effect |
| WO2012014207A2 (en) | 2010-07-27 | 2012-02-02 | Technion Research & Development Foundation Ltd. | Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles |
| WO2012014208A2 (en) | 2010-07-27 | 2012-02-02 | Yeda Research And Development Co. Ltd. | Methods and systems for assessing clonality of cell cultures |
| US9144585B2 (en) | 2010-07-27 | 2015-09-29 | Technion Research & Development Foundation Limited | Isolated mesenchymal progenitor cells and extracellular matrix produced thereby |
| WO2012017439A2 (en) | 2010-08-04 | 2012-02-09 | Ramot At Tel-Aviv University Ltd. | Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases |
| SG187830A1 (en) | 2010-08-22 | 2013-03-28 | Univ Ramot | Induced pluripotent stem cells derived from human pancreatic beta cells |
| WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
| WO2012028993A2 (en) | 2010-08-30 | 2012-03-08 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance |
| CA2810488C (en) | 2010-09-07 | 2025-05-06 | Technion Research & Development Foundation Limited | NEW PROCESSES AND CULTURE MEDIA FOR THE CULTURE OF MULTIPOTENTED STEM CELLS |
| WO2012032519A2 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of diagnosing parkinson's disease |
| WO2012032520A1 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease |
| WO2012032510A1 (en) | 2010-09-07 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Primers for amplifying dna and methods of selecting same |
| KR20130105652A (ko) | 2010-09-08 | 2013-09-25 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 안정하고 장기간의 인그래프트먼트를 위한 면역억제 약물의 조합 |
| MX357746B (es) | 2010-09-08 | 2018-07-23 | Yeda Res And Development Co Ltd Star | Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma. |
| CN103210082A (zh) | 2010-09-15 | 2013-07-17 | 雷蒙特亚特特拉维夫大学有限公司 | 扩增胰岛β细胞和使其再分化的方法 |
| US20130210901A1 (en) | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
| US8951983B2 (en) | 2010-10-17 | 2015-02-10 | Yeda Research And Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
| WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
| US20130216603A1 (en) | 2010-10-27 | 2013-08-22 | Nanocyte (Israel) Ltd. | Pharmaceutical compositions and delivery devices comprising stinging cells or capsules |
| ES2688457T3 (es) | 2010-10-28 | 2018-11-02 | Yeda Research And Development Co. Ltd. | Métodos de generación de anticuerpos contra metaloenzimas |
| BR112013010825A2 (pt) | 2010-11-03 | 2019-09-24 | Futuragene Israel Ltda | plantas transgênicas com rendimentos melhorados de sacarificação e métodos para geração das mesmas |
| WO2012059925A2 (en) | 2010-11-04 | 2012-05-10 | Ben-Gurion University Of The Negev Research And Development Authority | Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof |
| CN103298826A (zh) | 2010-11-15 | 2013-09-11 | 特拉维夫大学拉莫特有限公司 | 用于治疗淀粉样纤维形成相关疾病的二肽类似物 |
| EP2640404B1 (en) | 2010-11-17 | 2017-02-22 | Ben Gurion University of The Negev Research and Development Authority | T-cell therapy to neurodegenerative diseases |
| EP2646543A4 (en) | 2010-12-02 | 2014-09-03 | Technion Res & Dev Foundation | METHOD OF GENERATING CORNEAL CELLS AND CELL POPULATIONS THEREWITH |
| US20120183960A1 (en) | 2010-12-07 | 2012-07-19 | Enterologics, Inc. | Method for identifying e. coli m-17 |
| JP5922147B2 (ja) | 2010-12-15 | 2016-05-24 | カディマステム リミテッド | 多能性幹細胞に由来するインスリン産生細胞 |
| MX344728B (es) | 2010-12-22 | 2017-01-05 | Evogene Ltd | Polinucleótidos y polipéptidos aislados, y métodos para utilizarlos para aumentar la tolerancia al estrés abiótico, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o eficacia en el uso de nitrógeno de las plantas. |
| CN103533947A (zh) | 2010-12-28 | 2014-01-22 | 卡梅迪斯有限公司 | 用于治疗和预防感染的植物提取物 |
| CN103443270B (zh) | 2011-01-20 | 2017-06-06 | 普罗塔里克斯有限公司 | 用于在植物和植物细胞中表达α‑半乳糖苷酶的核酸构建体 |
| US20130316358A1 (en) | 2011-01-31 | 2013-11-28 | Yeda Research And Development Co. Ltd. | Methods of diagnosing disease using overlap extension pcr |
| WO2012114339A1 (en) | 2011-02-23 | 2012-08-30 | Rappaport Family Institute For Research In The Medical Sciences | High affinity molecules capable of binding a type a plexin receptor and uses of same |
| CN106978437A (zh) | 2011-03-02 | 2017-07-25 | 富途锐基尼以色列有限公司 | 具有功能失调的t3ss蛋白的抗菌性转基因植物 |
| EP2680864B1 (en) | 2011-03-03 | 2019-05-08 | Ramot at Tel-Aviv University Ltd. | Genetically modified muscle cells which express neurotrophic factors |
| WO2012120500A2 (en) | 2011-03-06 | 2012-09-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| US9061006B2 (en) | 2011-03-08 | 2015-06-23 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (PKU) |
| EP2685976B1 (en) | 2011-03-17 | 2017-12-27 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| IN2013MN01438A (da) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
| KR101903339B1 (ko) | 2011-03-22 | 2018-10-01 | 플루리스템 리미티드 | 방사선 또는 화학적 손상을 치료하는 방법 |
| WO2012127475A1 (en) | 2011-03-24 | 2012-09-27 | Neurim Pharmaceuticals (1991) Ltd. | Neuroprotective peptides |
| WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
| WO2012137202A1 (en) | 2011-04-05 | 2012-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci) |
| CA2832031C (en) | 2011-04-06 | 2019-09-17 | Ramot At Tel-Aviv University Ltd. | Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| SG10201601537QA (en) | 2011-04-15 | 2016-04-28 | Pluristem Ltd | Methods and systems for harvesting cells |
| US10760088B2 (en) | 2011-05-03 | 2020-09-01 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
| US9192670B2 (en) | 2011-05-04 | 2015-11-24 | Ramot At Tel-Aviv University Ltd. | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease |
| WO2012153333A1 (en) | 2011-05-09 | 2012-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Regeneration and repair of mesenchymal tissue using amelogenin |
| WO2012153336A2 (en) | 2011-05-12 | 2012-11-15 | Rakuto Bio Technologies Ltd. | Methods and device for lightening skin complexion |
| WO2012156976A1 (en) | 2011-05-16 | 2012-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of producing artemisinin in non-host plants and vectors for use in same |
| WO2012160526A2 (en) | 2011-05-23 | 2012-11-29 | Ofir Menashe | Formulations of microorganism comprising particles and uses of same |
| EP2715350B1 (en) | 2011-05-23 | 2017-09-27 | Yeda Research and Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| EP2714719B1 (en) | 2011-05-31 | 2018-12-12 | Hutchison Biofilm Medical Solutions Limited | Dispersion and detachment of cell aggregates |
| WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| EP2720720B1 (en) | 2011-06-14 | 2018-02-28 | Yeda Research and Development Co. Ltd. | Combination therapy to prevent dcis formation and progression to breast cancer |
| BR112013033096A2 (pt) | 2011-06-23 | 2017-01-24 | Kaiima Bio Agritech Ltd | trigo mole, plantas ou partes respectivas tendo genoma multiplicado parcial ou totalmente, híbridos e produtos respectivos e métodos de geração e uso respectivos |
| RU2014106125A (ru) | 2011-07-20 | 2015-08-27 | Каиима Био Агритех Лтд. | Растения кукурузы с частично или полностью умноженным геномом и их применения |
| US20130030452A1 (en) | 2011-07-27 | 2013-01-31 | Health Corporation - Rambam | Devices for surgical applications |
| US9150858B2 (en) | 2011-08-04 | 2015-10-06 | Yeda Research And Development Co. Ltd. | Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
| WO2013021389A2 (en) | 2011-08-09 | 2013-02-14 | Yeda Research And Development Co.Ltd. | Downregulation of mir-7 for promotion of beta cell differentiation and insulin production |
| RU2014108930A (ru) | 2011-08-14 | 2015-09-20 | Каиима Био Агритех Лтд. | Растения твердой пшеницы, обладающие частично или полностью умноженным геномом, и их применения |
| EP2753367A4 (en) | 2011-09-07 | 2015-10-14 | Yeda Res & Dev | OLFACTORY SIGNATURE AND ODORING MIXTURE THEREWITH |
| EP2753716B1 (en) | 2011-09-08 | 2017-11-01 | Yeda Research and Development Co. Ltd. | Novel risk biomarkers for lung cancer |
| AU2012305931B2 (en) | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
| EP3382027A3 (en) | 2011-09-13 | 2018-10-31 | Monsanto Technology LLC | Methods and compositions for weed control |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| MX361938B (es) | 2011-09-13 | 2018-12-19 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas. |
| WO2013040057A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
| CA2848695A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and composition for weed control comprising inhibiting ppg oxidase |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| AU2012325604B2 (en) | 2011-10-21 | 2017-08-03 | Augurex Life Sciences Corp. | Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis |
| EP2771464B1 (en) | 2011-10-27 | 2018-03-21 | Yeda Research and Development Co. Ltd. | Methods of treating cancer |
| JP6118331B2 (ja) | 2011-11-03 | 2017-04-19 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | 神経保護のための方法および組成物 |
| US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| US9736998B2 (en) | 2011-11-23 | 2017-08-22 | Danziger Dan Flower Farm | Otomeria plants |
| WO2013076730A1 (en) | 2011-11-27 | 2013-05-30 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis and compositions capable of same |
| KR20140102730A (ko) | 2011-12-08 | 2014-08-22 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 포유류 태아 폐 세포와 이를 치료용으로 사용하는 방법 |
| WO2013093921A1 (en) | 2011-12-20 | 2013-06-27 | Collplant Ltd. | Collagen coated synthetic polymer fibers |
| MX370404B (es) | 2011-12-22 | 2019-12-11 | Yeda Res & Dev | Uso de una terapia de combinación para inducir un injerto estable y a largo plazo. |
| US20130164193A1 (en) | 2011-12-22 | 2013-06-27 | Life Technologies Corporation | Sequential lateral flow capillary device for analyte determination |
| AR089461A1 (es) | 2011-12-28 | 2014-08-27 | Kaiima Bio Agritech Ltd | Una planta de sorghum cultivada que tiene un genoma parcial o totalmente multiplicado y usos de la misma |
| JP2015509085A (ja) | 2012-01-01 | 2015-03-26 | キュービーアイ エンタープライゼズ リミテッドQbi Enterprises Ltd. | 治療剤および診断剤の選択的送達のためのendo180を標的とする粒子 |
| WO2013114363A2 (en) | 2012-01-30 | 2013-08-08 | Yeda Research And Development Co.Ltd. | Antimicrobial agents |
| US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
| US10184131B2 (en) | 2012-02-06 | 2019-01-22 | A.B. Seeds Ltd. | Isolated polynucleotides expressing or modulating microRNAs or targets of same, transgenic plants comprising same and uses thereof |
| HK1202581A1 (en) | 2012-02-13 | 2015-10-02 | Gamida-Cell Ltd. | Mesenchymal stem cells conditioned medium and methods of generating and using the same |
| EP4488289A3 (en) | 2012-02-14 | 2025-03-19 | OPKO Biologics Ltd. | Long-acting coagulation factors and uses thereof |
| WO2013121405A1 (en) | 2012-02-19 | 2013-08-22 | Protalix Ltd. | Oral unit dosage forms and uses of same for the treatment of gaucher disease |
| EP2844744A2 (en) | 2012-02-22 | 2015-03-11 | Brainstem Biotec Ltd. | MicroRNAS FOR THE GENERATION OF ASTROCYTES |
| EP3401394A1 (en) | 2012-02-22 | 2018-11-14 | Exostem Biotec Ltd | Generation of neural stem cells |
| EP2833714A1 (en) | 2012-03-01 | 2015-02-11 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Male sterile garlic plants, hybrid offspring of same and methods of generating and using same |
| WO2013132495A1 (en) | 2012-03-07 | 2013-09-12 | Yeda Research And Development Co. Ltd. | Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same |
| WO2013140389A1 (en) | 2012-03-22 | 2013-09-26 | Ramot At Tel-Aviv University Ltd. | Plif multimeric peptides and uses thereof |
| EP2839015B1 (en) | 2012-04-18 | 2020-04-29 | Ramot at Tel-Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
| BR112014025951A2 (pt) | 2012-04-19 | 2017-07-11 | Opko Biologics Ltd | variantes de oxintomodulina de longa ação e métodos de produção do mesmo |
| US9439942B2 (en) | 2012-04-24 | 2016-09-13 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
| WO2013168164A1 (en) | 2012-05-09 | 2013-11-14 | Yeda Research And Development Co. Ltd. | Variants of tace pro-domain as tnf-a inhibitor and their medical use |
| US8865158B2 (en) | 2012-05-22 | 2014-10-21 | Ramot At Tel-Aviv University Ltd. | Bacteriophages for reducing toxicity of bacteria |
| EP2855521A4 (en) | 2012-05-24 | 2016-03-02 | Mountgate Group Ltd | COMPOSITIONS AND METHODS RELATED TO PREVENTING AND TREATING TOLL WUTINFECTION |
| MX360866B (es) | 2012-05-24 | 2018-11-09 | A B Seeds Ltd | Composiciones y métodos para silenciar la expresión genética. |
| US9731048B2 (en) | 2012-06-03 | 2017-08-15 | Ben-Gurion University Of The Negev Research And Development Authority | Functionalized titanium binding peptides and implants coated with same |
| MX362432B (es) | 2012-06-04 | 2019-01-17 | Opko Biologics Ltd | Variantes de oxm pegilada. |
| US10023474B2 (en) | 2012-07-03 | 2018-07-17 | Nanospun Technologies Ltd. | Methods for adsorption and biodegradation of petroleum |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| DK2880155T3 (da) | 2012-07-29 | 2019-07-15 | Yeda Res & Dev | Anvendelse af den reduktive glycinvej til generering af formatotrofiske og autotrofiske mikroorganismer |
| JP6340366B2 (ja) | 2012-07-31 | 2018-06-06 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 運動ニューロン疾患を診断および処置する方法 |
| DK2880151T3 (da) | 2012-08-06 | 2020-08-17 | Brainstorm Cell Therapeutics Ltd | Fremgangsmåder til frembringelse af mesenkymale stemceller, som udskiller neurotrofiske faktorer |
| WO2014033723A1 (en) | 2012-09-03 | 2014-03-06 | A.B. Seeds Ltd. | Method of improving abiotic stress tolerance of plants and plants generated thereby |
| US10543278B2 (en) | 2012-09-12 | 2020-01-28 | Ramot At Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
| WO2014057490A1 (en) | 2012-10-09 | 2014-04-17 | Ramot At Tel-Aviv University Ltd. | Methods and kits for predicting prognosis of cancer using soluble mortalin in blood |
| CN104918639B (zh) | 2012-10-22 | 2018-01-26 | 萨拜格Rfa公司 | 用于将治疗剂递送到活细胞和细胞核中的系统 |
| WO2014064682A1 (en) | 2012-10-24 | 2014-05-01 | Yeda Research And Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
| WO2014068553A1 (en) | 2012-10-29 | 2014-05-08 | Yeda Research And Development Co. Ltd. | Aptamers, multimeric aptamers and uses thereof |
| EA033788B1 (ru) | 2012-11-20 | 2019-11-26 | Opko Biologics Ltd | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина |
| WO2015079413A2 (en) | 2013-11-28 | 2015-06-04 | Yeda Research And Development Co. Ltd. | Synaptojanin-2 inhibitors and uses thereof |
| CN104822390A (zh) | 2012-11-29 | 2015-08-05 | 耶达研究及发展有限公司 | 预防肿瘤转移、癌症治疗和预后及鉴定为推定转移抑制剂的试剂的方法 |
| UY35252A (es) | 2013-01-01 | 2014-07-31 | Seeds Ltd Ab | MÉTODOS PARA INTRODUCIR dsRNA EN SEMILLAS DE PLANTAS PARA MODULAR LA EXPRESIÓN GENÉTICA |
| US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
| WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
| WO2014108850A2 (en) | 2013-01-09 | 2014-07-17 | Yeda Research And Development Co. Ltd. | High throughput transcriptome analysis |
| EP3431985A1 (en) | 2013-01-17 | 2019-01-23 | Novellusdx Ltd. | Methods and systems for identifying patient specific driver mutations |
| WO2014118785A1 (en) | 2013-02-04 | 2014-08-07 | Ramot At Tel-Aviv University Ltd. | Generation of cytotoxic tumor specific cell lines and uses thereof |
| CA2902727C (en) | 2013-03-06 | 2020-08-18 | Protalix Ltd. | Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy |
| US20160017020A1 (en) | 2013-03-06 | 2016-01-21 | Protalix Ltd. | Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same |
| BR112015023051A2 (pt) | 2013-03-13 | 2017-11-14 | Monsanto Technology Llc | método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo |
| US10612019B2 (en) | 2013-03-13 | 2020-04-07 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| ES2883580T3 (es) | 2013-03-21 | 2021-12-09 | Collplant Ltd | Composiciones que comprenden colágeno y PRP para la regeneración de tejidos y su método de producción |
| WO2014153394A1 (en) | 2013-03-21 | 2014-09-25 | Genisphere, Llc | Cellular delivery of dna intercalating agents |
| EP2978439B1 (en) | 2013-03-24 | 2017-08-16 | Biokine Therapeutics Ltd. | A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia |
| CN105377289A (zh) | 2013-04-21 | 2016-03-02 | 耶达研究及发展有限公司 | 用于下调Bcl-xL和/或Bcl-w的活性和/或量的试剂 |
| JP2016521971A (ja) | 2013-04-23 | 2016-07-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法119条第(e)項に基づき、2014年1月29日出願の米国特許仮出願第61/932,935号、2013年9月17日出願の米国特許仮出願第61/878,769号、および2013年4月23日出願の米国特許仮出願第61/814,920号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、YaqubHANNA、NoaNOVERSHTERN、およびYoachRAISによる米国特許出願(発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法(ISOLATEDNAIVEPLURIPOTENTSTEMCELLSANDMETHODSOFGENERATINGSAME)」)(代理人事件記録簿第58870号)にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。 |
| CN105555796B (zh) | 2013-04-25 | 2019-09-17 | 耶达研究及发展有限公司 | 抑制肽对治疗炎性疾病的用途 |
| US20160115231A1 (en) | 2013-05-21 | 2016-04-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
| WO2014191995A2 (en) | 2013-05-27 | 2014-12-04 | Rakuto Bio Technologies Ltd. | Enzymatic system-containing cosmetic compositions |
| ES2938044T3 (es) | 2013-06-24 | 2023-04-04 | Univ Ramot | Estructura a base de epiplón y sistema de suministro |
| EP3030663B1 (en) | 2013-07-19 | 2019-09-04 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
| US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
| WO2015015489A1 (en) | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
| EP3039030B1 (en) | 2013-08-29 | 2018-09-19 | Yeda Research and Development Co. Ltd. | Selective inhibitors of alpha2 isoform of na,k-atpase and use for reduction of intra-ocular pressure |
| IL228284A (en) | 2013-09-03 | 2016-12-29 | Technion Res & Dev Foundation | Implants from cellular scaffolding and blood vessel stalk |
| WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
| WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
| WO2015037009A1 (en) | 2013-09-16 | 2015-03-19 | Plexicure Ltd. | Isolated proteins capable of binding plexin-a4 and methods of producing and using same |
| US9695402B2 (en) | 2013-09-17 | 2017-07-04 | Yeda Research And Development Co. Ltd. | ERK-derived peptides and uses thereof |
| CN105960453A (zh) | 2013-10-01 | 2016-09-21 | 卡迪马干细胞有限公司 | 从人多能干细胞定向分化星形胶质细胞用于肌萎缩侧索硬化(als)的治疗和药物筛选 |
| EP3055066A4 (en) | 2013-10-07 | 2017-06-14 | Yeda Research and Development Co., Ltd. | Microfluidic device for analyzing gene expression |
| RU2746943C2 (ru) | 2013-10-21 | 2021-04-22 | Опко Байолоджикс Лтд. | Полипептиды длительного действия и способы их получения и введения |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| EP3060656A1 (en) | 2013-10-24 | 2016-08-31 | Yeda Research and Development Co., Ltd. | Polynucleotides encoding brex system polypeptides and methods of using same |
| CA2928315C (en) | 2013-10-31 | 2023-03-21 | Biokine Therapeutics Ltd. | Methods of treating acute myeloid leukemia with a flt3 mutation |
| AU2014341879B2 (en) | 2013-11-04 | 2020-07-23 | Greenlight Biosciences, Inc. | Compositions and methods for controlling arthropod parasite and pest infestations |
| CA2925698C (en) | 2013-11-28 | 2021-11-09 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| WO2015087327A1 (en) | 2013-12-10 | 2015-06-18 | Yeda Research And Development Co. Ltd. | Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-coa and bacteria expressing same |
| WO2015108982A2 (en) | 2014-01-15 | 2015-07-23 | Monsanto Technology Llc | Methods and compositions for weed control using epsps polynucleotides |
| WO2015114633A1 (en) | 2014-01-30 | 2015-08-06 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same |
| CA2937992A1 (en) | 2014-02-03 | 2015-08-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of eliminating stem cells |
| WO2015118537A2 (en) | 2014-02-05 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
| US10066014B2 (en) | 2014-02-06 | 2018-09-04 | Yeda Research And Development Co. Ltd. | Anti CD84 antibodies, compositions comprising same and uses thereof |
| WO2015118547A1 (en) | 2014-02-10 | 2015-08-13 | Protalix Ltd. | Method of maintaining disease stability in a subject having gaucher's disease |
| JP6628253B2 (ja) | 2014-02-11 | 2020-01-08 | ブレインストーム セル セラペウティクス リミテッド | 細胞の適性を判定する方法 |
| US20170067894A1 (en) | 2014-03-03 | 2017-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method and device for detection of pseudomonas aeruginosa |
| EP2923709A1 (en) | 2014-03-28 | 2015-09-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Multi-component-multistage malaria vaccine |
| WO2015153339A2 (en) | 2014-04-01 | 2015-10-08 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
| EP3129075B1 (en) | 2014-04-10 | 2024-09-18 | Bonus Therapeutics Ltd. | Bone repair compositions |
| EP3132055A2 (en) | 2014-04-14 | 2017-02-22 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | A method and kit for determining the tissue or cell origin of dna |
| WO2015159295A1 (en) | 2014-04-17 | 2015-10-22 | Yeda Research And Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| CN106573977B (zh) | 2014-04-27 | 2020-08-07 | 菲姆威有限公司 | 针对ceacam1的人源化抗体 |
| EP3058085B1 (en) | 2014-04-28 | 2021-02-17 | Yeda Research and Development Co., Ltd. | Microbiome response to agents |
| CN108064133A (zh) | 2014-05-04 | 2018-05-22 | 佛利斯特创新有限公司 | 用于蚊虫控制的组合物和所述组合物的用途 |
| US10294482B2 (en) | 2014-05-22 | 2019-05-21 | Yeda Research And Development Co. Ltd. | Recombinant microorganisms capable of carbon fixation |
| US20170253881A1 (en) | 2014-06-02 | 2017-09-07 | Technion Research & Development Foundation Limited | Compositions and methods of selectively inhibiting irp1 and treating inflammation |
| WO2015186128A1 (en) | 2014-06-02 | 2015-12-10 | Kadimastem Ltd. | Methods of inducing myelination and maturation of oligodendrocytes |
| CN106795515B (zh) | 2014-06-23 | 2021-06-08 | 孟山都技术公司 | 用于经由rna干扰调控基因表达的组合物和方法 |
| WO2015198320A1 (en) | 2014-06-24 | 2015-12-30 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
| CN106537148B (zh) | 2014-06-25 | 2019-10-11 | 泰尔哈绍梅尔医学研究基础设施和服务有限公司 | 癌症干细胞的鉴定及其用于诊断和治疗的用途 |
| US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| US10583084B2 (en) | 2014-06-26 | 2020-03-10 | Ramot At Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
| WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
| ES2799404T3 (es) | 2014-07-15 | 2020-12-17 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Polipéptidos de CD44 aislados y usos de los mismos |
| EP3172562B1 (en) | 2014-07-21 | 2019-03-13 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
| EP3172340B1 (en) | 2014-07-21 | 2019-02-20 | Novellusdx Ltd. | Methods for determining drug response of patient specific mutations |
| CN106604993A (zh) | 2014-07-29 | 2017-04-26 | 孟山都技术公司 | 用于控制昆虫害虫的组合物和方法 |
| US11920164B2 (en) | 2014-07-30 | 2024-03-05 | Yeda Research And Development Co. Ltd. | Media for culturing naive human pluripotent stem cells |
| BR112017002884A2 (pt) | 2014-08-14 | 2018-01-30 | Memed Diagnostics Ltd | ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano? |
| WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
| AU2015313811A1 (en) | 2014-09-08 | 2017-04-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) |
| CA2959716A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| EP2992895A1 (en) | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
| CA2972739A1 (en) | 2014-09-11 | 2016-03-17 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of producing mogrosides and compositions comprising same and uses thereof |
| IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
| CN106999608A (zh) | 2014-09-21 | 2017-08-01 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 为了治疗脂质相关病症而下调mir‑132 |
| DE102015220401B4 (de) | 2014-10-20 | 2022-12-29 | Gen-Probe Incorporated | Erythrozyten-Lyselösung |
| US10570368B2 (en) | 2014-11-13 | 2020-02-25 | Enzootic Holdings Ltd. | Functional sex-reversal of decapod crustacean females |
| JP2017533723A (ja) | 2014-11-17 | 2017-11-16 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | マイクロバイオーム解析方法 |
| WO2016079736A2 (en) | 2014-11-17 | 2016-05-26 | Yeda Research And Development Co. Ltd. | Methods of treating diseases related to mitochondrial function |
| WO2016079739A2 (en) | 2014-11-20 | 2016-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells |
| WO2016084088A1 (en) | 2014-11-26 | 2016-06-02 | Ramot At Tel-Aviv University Ltd. | Targeted elimination of bacterial genes |
| EP3224363B1 (en) | 2014-11-27 | 2021-11-03 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Nucleic acid constructs for genome editing |
| HRP20230405T8 (hr) | 2014-12-10 | 2023-09-29 | Opko Biologics Ltd. | Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta |
| WO2016092555A2 (en) | 2014-12-11 | 2016-06-16 | Yeda Research And Development Co. Ltd. | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
| CN111624345A (zh) | 2014-12-11 | 2020-09-04 | 米密德诊断学有限公司 | 用于诊断多种感染的标记组合及其使用方法 |
| WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
| KR20170115514A (ko) | 2014-12-30 | 2017-10-17 | 셀 큐어 뉴로사이언시스 리미티드 | Rpe 세포 집단 및 이를 생성하는 방법 |
| WO2016108240A1 (en) | 2014-12-30 | 2016-07-07 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
| CN114533761A (zh) | 2014-12-30 | 2022-05-27 | 细胞治疗神经科学有限公司 | 治疗视网膜疾病的方法 |
| IL253208B2 (en) | 2015-01-04 | 2023-03-01 | Protalix Ltd | Converted DNase and its uses |
| WO2016116935A1 (en) | 2015-01-21 | 2016-07-28 | Yeda Research And Development Co. Ltd. | Use of rasa2 as a prognostic and therapeutic marker for melanoma |
| CN108064288B (zh) | 2015-01-22 | 2021-11-26 | 孟山都技术公司 | 用于控制叶甲属的组合物和方法 |
| EP3261612A1 (en) | 2015-02-26 | 2018-01-03 | Yeda Research and Development Co. Ltd | Method of promoting hair growth |
| EP3268475B1 (en) | 2015-03-11 | 2020-10-21 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Decoy oligonucleotides for the treatment of diseases |
| IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
| AU2016243124A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | CAR T-cell therapy directed to LHR for the treatment of solid tumors |
| WO2016157175A1 (en) | 2015-03-27 | 2016-10-06 | Yeda Research And Development Co. Ltd. | Methods of treating motor neuron diseases |
| CN107771217A (zh) | 2015-03-31 | 2018-03-06 | 耶达研究及发展有限公司 | 谷氨酸草酰乙酸转氨酶1 (got1)、制剂和产生它们的方法及其用途 |
| EP3277260B1 (en) | 2015-04-01 | 2021-05-12 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Erodium crassifolium l'her plant extracts and uses thereof |
| AU2016245434B2 (en) | 2015-04-07 | 2020-10-29 | Ela Pharma Ltd | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto |
| EP3081575A1 (en) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
| CA2986202C (en) | 2015-04-27 | 2023-08-22 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions |
| ES2911341T3 (es) | 2015-04-29 | 2022-05-18 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Composiciones antifitopatogénicas |
| WO2016174652A1 (en) | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
| EP3292219B9 (en) | 2015-05-04 | 2022-05-18 | Ramot at Tel-Aviv University Ltd. | Methods and kits for fragmenting dna |
| EP3294280A1 (en) | 2015-05-11 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
| EP3298141A4 (en) | 2015-05-17 | 2019-01-09 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
| WO2016185481A2 (en) | 2015-05-20 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
| BR112017024928A2 (pt) | 2015-05-21 | 2018-07-31 | Yeda Research And Development Co Ltd | Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica |
| JP2018517697A (ja) | 2015-05-29 | 2018-07-05 | オプコ バイオロジクス リミテッド | ペグ化オキシントモジュリン変異体 |
| EP3302053B1 (en) | 2015-06-02 | 2021-03-17 | Monsanto Technology LLC | Compositions and methods for delivery of a polynucleotide into a plant |
| WO2016196782A1 (en) | 2015-06-03 | 2016-12-08 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
| JP7010473B2 (ja) | 2015-06-04 | 2022-02-10 | ユニバーシティ オブ サザン カリフォルニア | Lym-1およびlym-2標的化car細胞免疫療法 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| WO2016203476A1 (en) | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
| ES2917884T3 (es) | 2015-06-18 | 2022-07-12 | Yeda Res & Dev | Protocolos de acondicionamiento y uso de los mismos para la regeneración de tejidos |
| ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
| IL274572B2 (en) | 2015-07-16 | 2024-01-01 | Biolinerx Ltd | Compositions and methods for treating cancer |
| JP7057748B2 (ja) | 2015-07-16 | 2022-04-20 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 遺伝子改変された抗第三者中枢性メモリーt細胞および免疫療法におけるその使用 |
| WO2017013648A1 (en) | 2015-07-19 | 2017-01-26 | Yeda Research And Development Co. Ltd. | SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE |
| BR112018001310A2 (en) | 2015-07-22 | 2018-09-11 | Phytopharma International Ltd. | bee-ingestible compositions, methods of use thereof for the production of honey and honey produced by these |
| WO2017017686A1 (en) | 2015-07-29 | 2017-02-02 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
| ES2965461T3 (es) | 2015-08-03 | 2024-04-15 | Biokine Therapeutics Ltd | Inhibidor de CXCR4 para el tratamiento del cáncer |
| EP3332009A1 (en) | 2015-08-04 | 2018-06-13 | Yeda Research and Development Co., Ltd. | Methods of screening for riboswitches and attenuators |
| WO2017021973A1 (en) | 2015-08-05 | 2017-02-09 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
| EP3331995A1 (en) | 2015-08-05 | 2018-06-13 | Cell Cure Neurosciences Ltd. | Preparation of photoreceptors for the treatment of retinal diseases |
| WO2017025963A1 (en) | 2015-08-10 | 2017-02-16 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods and pharmaceutical compositions for improving wound healing using cd24 |
| US20180237790A1 (en) | 2015-08-13 | 2018-08-23 | Forrest Innovation Ltd. | Formulations and compositions for delivery of nucleic acids to plant cells |
| WO2017033188A1 (en) | 2015-08-24 | 2017-03-02 | Yeda Research And Development Co. Ltd. | Algal oil and biofuel and methods of producing same |
| US10765706B2 (en) | 2015-09-03 | 2020-09-08 | University Of South Florida | Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers |
| WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
| WO2017072757A1 (en) | 2015-10-25 | 2017-05-04 | Yeda Research And Development Co. Ltd. | Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same |
| US12188047B2 (en) | 2015-10-26 | 2025-01-07 | Hadasit Medical Research Services And Development Ltd. | Preparation of retinal pigment epithelium cells |
| WO2017072773A1 (en) | 2015-10-27 | 2017-05-04 | Ilana Nathan | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
| IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method of inducing cardiomyocytes proliferation and treating heart diseases |
| EP3370791A1 (en) | 2015-11-03 | 2018-09-12 | Ariel-University Research and Development Company Ltd. | Compositions for regeneration and repair of neural tissue |
| WO2017081689A1 (en) | 2015-11-11 | 2017-05-18 | Ramot At Tel-Aviv University Ltd. | Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer |
| BR112018010946A2 (en) | 2015-11-30 | 2018-12-04 | Kadimastem Ltd | pancreatic endocrine cell enrichment method, pancreatic endocrine cell enriched population, diabetes treatment method and insulin production beta cell preparation method |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| US11213609B2 (en) | 2015-12-16 | 2022-01-04 | Ramot At Tel-Aviv University Ltd. | Particles comprising decellularized omentum |
| WO2017115367A1 (en) | 2015-12-28 | 2017-07-06 | The National Institute for Biotechnology in the Negev Ltd. | Composition and method for treating amyotrophic lateral sclerosis |
| JP2019505511A (ja) | 2016-01-06 | 2019-02-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 |
| WO2017122203A1 (en) | 2016-01-11 | 2017-07-20 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
| CN109068605B (zh) | 2016-01-21 | 2022-11-11 | 以色列国家农业和农村发展农业研究组织沃尔坎尼中心 | 单性结实植物及其产生方法 |
| IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | The composition containing sp1 protein and carbon nanoparticles and its uses |
| IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive wires |
| WO2017130205A1 (en) | 2016-01-31 | 2017-08-03 | Hadasit Medical Research Services And Development Ltd. | Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof |
| AU2017214733B2 (en) | 2016-02-04 | 2022-09-29 | Yeda Research And Development Co. Ltd. | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53 |
| WO2017138008A2 (en) | 2016-02-14 | 2017-08-17 | Yeda Research And Development Co. Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
| EP3414346B1 (en) | 2016-02-14 | 2019-11-13 | Yeda Research and Development Co. Ltd. | Microbiome-based diagnosis, prediction and treatment of relapsing obesity |
| US20190246638A1 (en) | 2016-02-16 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd, | Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth |
| IL260983B (en) | 2016-02-19 | 2022-07-01 | Genisphere Llc | Nucleic acid carriers and methods of medical use |
| WO2017145162A1 (en) | 2016-02-23 | 2017-08-31 | Chaya Brodie | Generation of cancer stem cells and use thereof |
| MX2018010445A (es) | 2016-03-01 | 2019-10-17 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
| IL287757B (en) | 2016-03-03 | 2022-07-01 | Memed Diagnostics Ltd | Analyzing rna for diagnosing infection type |
| US20190216891A1 (en) | 2016-03-06 | 2019-07-18 | Yeda Research And Development Co., Ltd. | Method for modulating myelination |
| IL244649A0 (en) | 2016-03-17 | 2016-06-30 | Yeda Res & Dev | Methods for the isolation of barrel-like proteases and the identification of peptides that are cleaved by Alidan |
| EP3440461A4 (en) | 2016-04-06 | 2019-11-06 | Technion Research & Development Foundation Limited | INFILTRATING IMMUNEAN PARTS FOR PREDICTING AN ANTI-TNF ANSWER IN THICK DARM BIOPSIA |
| US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
| CA3021914C (en) | 2016-04-27 | 2024-04-30 | Gen-Probe Incorporated | Blood cell lysis reagent |
| WO2017203520A1 (en) | 2016-05-22 | 2017-11-30 | Yeda Research And Development Co. Ltd. | Methods of using pulmonary cells for transplantation and induction of tolerance |
| IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
| WO2017208247A1 (en) | 2016-06-02 | 2017-12-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
| EP3464322B1 (en) | 2016-06-05 | 2023-04-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Novel molecules for the treatment of inflammation |
| EP3468610A1 (en) | 2016-06-09 | 2019-04-17 | OPKO Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
| WO2017221225A1 (en) | 2016-06-19 | 2017-12-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Screening for chemotherapy resistance in human haploid cells |
| MX2019000022A (es) | 2016-06-27 | 2019-09-18 | Yeda Res & Dev | Células veto generadas a partir de linfocitos t de memoria. |
| EP3482200B1 (en) | 2016-07-10 | 2022-05-04 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| EP3482201B1 (en) | 2016-07-10 | 2022-12-14 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| IL246722A0 (en) | 2016-07-11 | 2016-09-29 | Yeda Res & Dev | Combination therapy to increase endogenous nitric oxide (no) synthesis |
| KR20190038833A (ko) | 2016-07-11 | 2019-04-09 | 보누스 테라퓨틱스 리미티드 | 조직 재생용 세포 조성물 |
| MY206271A (en) | 2016-07-11 | 2024-12-06 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
| IL302693B2 (en) | 2016-07-11 | 2025-10-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Methods and systems for growing cells in culture |
| EP4434516A3 (en) | 2016-07-18 | 2025-02-26 | Ramot at Tel-Aviv University Ltd. | Modular platform for targeted therapeutics |
| US20190203270A1 (en) | 2016-07-24 | 2019-07-04 | Yeda Research And Development Co., Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
| ES2965761T3 (es) | 2016-08-08 | 2024-04-16 | Tech Innovation Momentum Fund Israel Limited Partnership | Sistemas bacterianos para el análisis de polipéptidos ubiquitilados |
| US10633706B2 (en) | 2016-08-10 | 2020-04-28 | Ramot At Tel-Aviv University Ltd. | Analysis of methylation status and copy number |
| US12205677B2 (en) | 2016-08-10 | 2025-01-21 | Memed Diagnostics Ltd. | System and method for analysis of biological data |
| SG11201901272WA (en) | 2016-08-14 | 2019-03-28 | Univ Ramot | Mesenchymal cell-derived exosomes to treat neurological disorders |
| IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
| WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
| PE20190839A1 (es) | 2016-08-28 | 2019-06-17 | The State Of Israel Ministry Of Agriculture And Rural Development Agricultural Res Organization Aro | Metodo para controlar infecciones fungicas en plantas |
| EP3510047A1 (en) | 2016-09-07 | 2019-07-17 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
| EP3512943B1 (en) | 2016-09-14 | 2023-04-12 | Yeda Research and Development Co. Ltd. | Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| IL248468A0 (en) | 2016-10-13 | 2017-01-31 | Technion Res & Dev Foundation | Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing |
| IL248385A0 (en) | 2016-10-18 | 2017-02-01 | Yeda Res & Dev | Treatment of circadian rhythm disorder |
| EP3538651A1 (en) | 2016-11-10 | 2019-09-18 | Yeda Research and Development Co., Ltd. | Phosphotriesterases for treating or preventing organophosphate exposure associated damage |
| CN110234765A (zh) | 2016-11-28 | 2019-09-13 | 耶达研究及发展有限公司 | 分离的多核苷酸和多肽及使用它们来表达感兴趣的表达产物的方法 |
| US20190343782A1 (en) | 2016-11-30 | 2019-11-14 | Yeda Research And Development Co. Ltd. | Methods of treating liver toxicity and disorders |
| SG11201810936VA (en) | 2016-12-01 | 2019-01-30 | Univ Ramot | Combined treatment for nerve injuries |
| CN110392736A (zh) | 2017-01-18 | 2019-10-29 | 耶达研究及发展有限公司 | 遗传修饰的反抑细胞及其在免疫治疗中的用途 |
| WO2018138668A1 (en) | 2017-01-25 | 2018-08-02 | Mor Research Applications Ltd. | Methods of diagnosing malignant diseases |
| IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production |
| CA3052872A1 (en) | 2017-02-08 | 2018-08-16 | Hadasit Medical Research Services And Development Ltd. | Photoreceptor cells for the treatment of retinal diseases |
| IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
| WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| WO2018167778A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and prognosing cancer |
| EP3595687A1 (en) | 2017-03-16 | 2020-01-22 | Lineage Cell Therapeutics, Inc. | Methods for measuring therapeutic effects of retinal disease therapies |
| HRP20231499T1 (hr) | 2017-04-05 | 2024-03-01 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Ex-vivo sustav kulture i metode korištenja istog |
| IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
| JP7445429B2 (ja) | 2017-05-10 | 2024-03-07 | アリエル サイエンティフィック イノベーションズ リミテッド | 抗体の精製法 |
| ES2939298T3 (es) | 2017-05-21 | 2023-04-20 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Combinación de marcadores para el diagnóstico del cáncer |
| US20200172604A1 (en) | 2017-05-23 | 2020-06-04 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
| GB201708665D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
| GB201708662D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing shelf-life of banana |
| EP3630973A1 (en) | 2017-05-31 | 2020-04-08 | Tropic Biosciences UK Limited | Methods of selecting cells comprising genome editing events |
| WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
| US11466323B2 (en) | 2017-07-13 | 2022-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules |
| EP3652344A1 (en) | 2017-07-13 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Dna targets as tissue-specific methylation markers |
| US20200165671A1 (en) | 2017-07-13 | 2020-05-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Detecting tissue-specific dna |
| IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
| WO2019030759A1 (en) | 2017-08-08 | 2019-02-14 | Technology Innovation Momentum Fund (Israel) Limited Partnership | CHLORAMPHENICOL-RESISTANT TRUNCATED PROTEIN AND USES THEREOF |
| IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
| US11619634B2 (en) | 2017-08-21 | 2023-04-04 | Savicell Diagnostic Ltd. | Methods of diagnosing and treating lung cancer |
| US11692166B2 (en) | 2017-08-23 | 2023-07-04 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
| US20200270604A1 (en) | 2017-09-19 | 2020-08-27 | Tropic Biosciences UK Limited | Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells |
| WO2019058376A1 (en) | 2017-09-19 | 2019-03-28 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | BIRDS WITH GENOME EDITION |
| CN111565731B (zh) | 2017-10-24 | 2024-03-08 | 达莉亚·伊兰妮 | 治疗缺血性疾病的方法 |
| EP3706795A4 (en) | 2017-11-09 | 2021-10-13 | Pinteon Therapeutics Inc. | METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES |
| IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
| BR112020010830A2 (pt) | 2017-11-29 | 2020-11-10 | Weedout Ltd. | composições, kits e métodos para controlar erva daninha do gênero amaranthus |
| IL274979B2 (en) | 2017-11-29 | 2024-07-01 | Univ Ramot | Methods for the prevention and treatment of neurogenic seizures |
| EP3716993A1 (en) | 2017-12-03 | 2020-10-07 | Yeda Research and Development Co. Ltd | Treatment of an ischemic heart disease |
| EP3723785A1 (en) | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Cop9 signalosome (csn) complex modulators and uses thereof |
| EP3731965A1 (en) | 2017-12-28 | 2020-11-04 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method to reproduce circadian rhythms on a microfluidic chip |
| BR112020013238A2 (pt) | 2017-12-29 | 2020-12-01 | Cell Cure Neurosciences Ltd. | composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana |
| US20210112739A1 (en) | 2018-01-29 | 2021-04-22 | Lavie Bio Ltd | Plant microbial preparations, compositions and formulations comprising same and uses thereof |
| IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| IL257269A (en) | 2018-01-31 | 2018-04-09 | Olender Tsviya | Signaling is directed to the endoplasmic reticulum |
| EP3749368A1 (en) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
| WO2019155459A1 (en) | 2018-02-08 | 2019-08-15 | Yeda Research And Development Co. Ltd. | Inhibitors of the 20s proteasome |
| WO2019162945A1 (en) | 2018-02-23 | 2019-08-29 | Carmel Haifa University Economic Corporation Ltd. | Methods for treating memory impairment and cognitive dysfunction |
| US20200408761A1 (en) | 2018-02-28 | 2020-12-31 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of diagnosing and treating bladder cancer |
| WO2019175869A1 (en) | 2018-03-12 | 2019-09-19 | Yeda Research And Development Co. Ltd | Treatment of a heart disease |
| EP3765031A4 (en) | 2018-03-14 | 2022-03-23 | Memorial Sloan Kettering Cancer Center | ANTI-POLYSIAL ACID ANTIBODIES AND USES THEREOF |
| US11648260B2 (en) | 2018-03-29 | 2023-05-16 | Technion Research And Development Foundation Limitted | Vesicles comprising a PTEN inhibitor and uses of same |
| EP3774047A1 (en) | 2018-03-29 | 2021-02-17 | Yeda Research and Development Co. Ltd | Use of electric field gradients to control gene expression |
| IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
| GB201807192D0 (en) | 2018-05-01 | 2018-06-13 | Tropic Biosciences Uk Ltd | Compositions and methods for reducing caffeine content in coffee beans |
| IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neoantigens |
| WO2019220441A1 (en) | 2018-05-15 | 2019-11-21 | Hadasit Medical Research Services And Development Ltd. | Compositions and methods for treating cancer resistant to an anti-cancer agent |
| EP3801614A1 (en) | 2018-05-27 | 2021-04-14 | BioLineRx Ltd. | Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors |
| EP3785279A4 (en) | 2018-05-31 | 2022-07-27 | Immunity Pharma Ltd. | COMPOSITIONS AND METHODS OF USE THEREOF IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| EP3802839A1 (en) | 2018-06-07 | 2021-04-14 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Nucleic acid constructs and methods of using same |
| EP3800998A1 (en) | 2018-06-07 | 2021-04-14 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Methods of regenerating and transforming cannabis |
| WO2020003311A1 (en) | 2018-06-25 | 2020-01-02 | Yeda Research And Development Co. Ltd. | Systems and methods for increasing efficiency of genome editing |
| WO2020008412A1 (en) | 2018-07-04 | 2020-01-09 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
| EP3818529A2 (en) | 2018-07-08 | 2021-05-12 | Yeda Research and Development Co. Ltd | Person-specific assessment of probiotics responsiveness |
| US12134638B2 (en) | 2018-07-11 | 2024-11-05 | Kahr Medical Ltd. | SIRPalpha-4-1BBL variant fusion protein and methods of use thereof |
| SG11202012773QA (en) | 2018-07-11 | 2021-01-28 | Immunity Pharma Ltd | Peptide compounds and therapeutic uses of same |
| AU2019315054A1 (en) | 2018-07-31 | 2021-03-18 | Collplant Ltd. | Tobacco transgenic event and methods for detection and use thereof |
| IL261156A (en) | 2018-08-14 | 2020-02-27 | Fass Deborah | Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same |
| EP3841201A1 (en) | 2018-08-24 | 2021-06-30 | Yeda Research and Development Co. Ltd | Methods of modulating m2 macrophage polarization and use of same in therapy |
| WO2020058979A2 (en) | 2018-09-20 | 2020-03-26 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral sclerosis |
| EP3856225A1 (en) | 2018-09-25 | 2021-08-04 | BioLineRx Ltd. | Methods of selecting treatment for cxcr4-associated cancer |
| IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| US12478571B2 (en) | 2018-12-17 | 2025-11-25 | Pontis Biologics, Inc. | Enzyme based compositions and methods for removing dental calculi |
| WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
| SG11202107720UA (en) | 2019-01-31 | 2021-08-30 | Agency Science Tech & Res | Cnx/erp57 inhibitor for use in the treatment or prevention of cancer |
| IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof |
| IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
| EP3927378A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
| EP3927807A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods of generating organoids for high throughput screening of drugs |
| IL286011B2 (en) | 2019-03-05 | 2024-06-01 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Genome-edited birds |
| EP3938400B1 (en) | 2019-03-11 | 2025-07-30 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
| GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
| GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
| GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
| IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Bistable type ii opsins and uses thereof |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| EP3946611A2 (en) | 2019-03-31 | 2022-02-09 | Yeda Research and Development Co. Ltd | Anti-viral and anti-tumoral compounds |
| IL266433B (en) | 2019-05-02 | 2020-11-30 | Sagi Irit | Preparations containing the propeptide of lysyl oxidase and their uses |
| EP3969619A1 (en) | 2019-05-13 | 2022-03-23 | Yeda Research and Development Co. Ltd | Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases |
| IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| JP7664856B2 (ja) | 2019-05-22 | 2025-04-18 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | ヒト多能性細胞を培養する方法 |
| CA3140406A1 (en) | 2019-05-28 | 2020-12-03 | Shanghaitech University | Composition and methods to treat ectodermal dysplasia 2, clouston type |
| AU2020291694B2 (en) | 2019-06-12 | 2025-10-02 | Hadasit Medical Research Services And Development Ltd. | Methods of generating oligodendrocytes |
| EP3983540A1 (en) | 2019-06-16 | 2022-04-20 | Yeda Research and Development Co. Ltd | Method for stabilizing intracellular rna |
| WO2020261281A1 (en) | 2019-06-27 | 2020-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
| KR20220042139A (ko) | 2019-07-04 | 2022-04-04 | 유코 아이엔씨. | 에피토프 제거된 알파 글리아딘 및 복강병 및 글루텐 민감성의 관리를 위한 이의 용도 |
| US20220267409A1 (en) | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
| US20220281960A1 (en) | 2019-07-16 | 2022-09-08 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for the treatment of tuberculosis |
| IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
| EP4004548B1 (en) | 2019-07-29 | 2026-01-14 | Yeda Research and Development Co. Ltd | Methods of treating and diagnosing lung cancer |
| US20220298522A1 (en) | 2019-07-30 | 2022-09-22 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
| WO2021028909A1 (en) | 2019-08-12 | 2021-02-18 | Yeda Research And Development Co. Ltd. | Dna repair blood test for predicting response of lung cancer patients to immunotherapy |
| US20240140988A1 (en) | 2019-08-22 | 2024-05-02 | Ariel Scientific Innovations Ltd. | Scaled-up methods for purifying antibodies |
| EP4021463A1 (en) | 2019-08-27 | 2022-07-06 | Yeda Research and Development Co. Ltd | Treatment of bacterial vaginosis |
| WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
| IL269674B (en) | 2019-09-25 | 2020-08-31 | Roy Bar Ziv | Assembling protein complexes on a chip |
| WO2021070181A1 (en) | 2019-10-08 | 2021-04-15 | Nectin Therapeutics Ltd. | Antibodies against the poliovirus receptor (pvr) and uses thereof |
| IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
| WO2021084526A1 (en) | 2019-10-31 | 2021-05-06 | Yeda Research And Development Co. Ltd. | Engineered autotrophic bacteria for co2 conversion to organic materials |
| BR112022009087A2 (pt) | 2019-11-11 | 2022-07-26 | Ibi Ag Innovative Bio Insecticides Ltd | Nanocorpos para controle de insetos e usos dos mesmos |
| US12385054B2 (en) | 2019-11-19 | 2025-08-12 | Protalix Ltd. | Removal of constructs from transformed cells |
| IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
| EP4077731A1 (en) | 2019-12-22 | 2022-10-26 | Yeda Research and Development Co. Ltd | Diagnosis of frontotemporal dementia |
| IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | System and methods for identifying cells that have undergone genome editing |
| IL271778A (en) | 2019-12-31 | 2021-06-30 | Ichilov Tech Ltd | Methods for treating atopic dermatitis |
| WO2021137231A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
| US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
| IL272074B2 (en) | 2020-01-15 | 2024-12-01 | Immunity Pharma Ltd | Peptide compounds and methods of treating diseases using same |
| JP7685766B2 (ja) | 2020-01-22 | 2025-05-30 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 抗ide抗体およびその使用 |
| IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
| WO2021152584A1 (en) | 2020-01-28 | 2021-08-05 | Ariel Scientific Innovations Ltd. | Methods of analyzing cell membranes |
| IL295179A (en) | 2020-01-29 | 2022-09-01 | Memed Diagnostics Ltd | Methods for diagnosis and classification of viral infections |
| IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
| WO2021152587A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Treating acute liver disease with tlr-mik inhibitors |
| IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
| WO2021152586A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
| CN115335532A (zh) | 2020-02-09 | 2022-11-11 | Nlc制药有限公司 | Sars-cov-2快速检测测试 |
| IL272586A (en) | 2020-02-10 | 2021-08-31 | Yeda Res & Dev | A method for cell cluster analysis |
| EP4110823A1 (en) | 2020-02-26 | 2023-01-04 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
| US20230127559A1 (en) | 2020-03-16 | 2023-04-27 | Yeda Research And Development Co. Ltd. | Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein |
| KR20230003492A (ko) | 2020-03-29 | 2023-01-06 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 고셔병 치료용 베타-글루코세레브로시다아제 변이체 |
| WO2021199047A1 (en) | 2020-03-31 | 2021-10-07 | Biomuse Ltd. | Bacteria for the prevention and treatment of smoke-induced lung damage |
| EP4133107A1 (en) | 2020-04-06 | 2023-02-15 | Yeda Research and Development Co. Ltd | Methods of diagnosing cancer and predicting responsiveness to therapy |
| EP4132479A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
| CA3177360A1 (en) | 2020-04-13 | 2021-10-21 | Exoprother Medical Ltd. | Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy |
| US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| WO2021229577A1 (en) | 2020-05-12 | 2021-11-18 | Collplant Ltd. | Collagen as a delivery tool for metal-based anti-viral agents |
| IL274811B (en) | 2020-05-20 | 2021-05-31 | Yeda Res & Dev | Spatial information is developed for the analysis of individual cells |
| IL298934A (en) | 2020-06-10 | 2023-02-01 | Univ Ramot | Methods for identifying CpGs are implicated |
| WO2021260696A1 (en) | 2020-06-22 | 2021-12-30 | Ramot At Tel-Aviv University Ltd. | Multi subunit protein modules, cells expressing same and uses thereof |
| US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
| IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
| WO2022038539A2 (en) | 2020-08-18 | 2022-02-24 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
| US20230309480A1 (en) | 2020-08-18 | 2023-10-05 | International Rice Research Institute | Methods of increasing outcrossing rates in gramineae |
| IL277488A (en) | 2020-09-21 | 2022-04-01 | Yeda Res & Dev | Weight regulation method |
| WO2022064494A2 (en) | 2020-09-23 | 2022-03-31 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating coronaviral infections |
| IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | A method for diagnosing breast cancer |
| EP4225902A1 (en) | 2020-10-05 | 2023-08-16 | Protalix Ltd. | Dicer-like knock-out plant cells |
| CN116635056A (zh) | 2020-10-07 | 2023-08-22 | 波塔力克斯有限公司 | 长效脱氧核糖核酸酶 |
| WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
| IL278401A (en) | 2020-10-29 | 2022-05-01 | Yeda Res & Dev | Polynucleotides for editing RNA and a method for using them |
| EP4240856A2 (en) | 2020-11-09 | 2023-09-13 | 1E Therapeutics, Ltd. | Catalytic sequence based methods of treating or preventing bacterial infections |
| AU2021387979A1 (en) | 2020-11-26 | 2023-03-30 | Ukko Inc. | Modified high molecular weight glutenin subunit and uses thereof |
| IL279559A (en) | 2020-12-17 | 2022-07-01 | Yeda Res & Dev | Controlling ubiquitination of mlkl for treatment of disease |
| EP4267741A2 (en) | 2020-12-28 | 2023-11-01 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
| WO2022144883A2 (en) | 2020-12-28 | 2022-07-07 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
| AU2022206415A1 (en) | 2021-01-10 | 2023-08-17 | Supermeat The Essence Of Meat Ltd. | Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry |
| US20240083843A1 (en) | 2021-01-14 | 2024-03-14 | Yeda Research And Development Co. Ltd. | Methods of producing vitamin d |
| IL280340B (en) | 2021-01-21 | 2022-04-01 | Yeda Res & Dev | Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection |
| JP2024506954A (ja) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ワクチン作製用の遺伝子改変細菌 |
| EP4294428A1 (en) | 2021-02-18 | 2023-12-27 | Yeda Research and Development Co. Ltd | Method of generating vaccines |
| IL281561A (en) | 2021-03-16 | 2022-10-01 | Yeda Res & Dev | Methods and devices for ex-utero mouse embryonic development |
| AU2022247325A1 (en) | 2021-03-30 | 2023-10-05 | Biomx Ltd. | Pseudomonas bacteriophage and uses thereof |
| IL282188A (en) | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | Combined use of ketamine and bretigabine for the treatment of psychiatric disorders |
| WO2022238947A1 (en) | 2021-05-12 | 2022-11-17 | Biomx Ltd. | Staphylococcus bacteriophage and uses thereof |
| IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases |
| EP4352509A1 (en) | 2021-06-06 | 2024-04-17 | Yeda Research and Development Co. Ltd | Combined treatment for cancer |
| WO2022264132A1 (en) | 2021-06-13 | 2022-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming human cells |
| CR20240020A (es) | 2021-06-16 | 2024-02-28 | Seedx Tech Inc | Métodos de clasificación de semillas de matthiola |
| NL2028466B1 (en) | 2021-06-16 | 2022-12-21 | Sakata Holland B V | Methods of sorting matthiola seeds |
| EP4362662A1 (en) | 2021-07-02 | 2024-05-08 | Tropic Biosciences UK Limited | Delay or prevention of browning in banana fruit |
| WO2023286059A1 (en) | 2021-07-13 | 2023-01-19 | Technion Research & Development Foundation Limited | Compositions and methods for treating a medical condition |
| EP4373919A1 (en) | 2021-07-18 | 2024-05-29 | Gamida-Cell Ltd. | Therapeutic nk cell populations |
| WO2023002492A1 (en) | 2021-07-22 | 2023-01-26 | Yeda Research And Development Co. Ltd. | Codon optimization of nucleic acids |
| EP4380966A2 (en) | 2021-08-03 | 2024-06-12 | Genicity Limited | Engineered tcr complex and methods of using same |
| EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
| EP4384603A1 (en) | 2021-08-10 | 2024-06-19 | Gamida-Cell Ltd. | Engineered nk cells, methods of their production and uses thereof |
| GB202112866D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to fusarium wilt in a banana |
| GB202112865D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to black sigatoka disease in banana |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| CN118696122A (zh) | 2021-12-08 | 2024-09-24 | 耶达研究及发展有限公司 | 用于肺再生的多能肺祖细胞 |
| EP4499108A1 (en) | 2022-04-25 | 2025-02-05 | Yeda Research and Development Co. Ltd | Compositions for altering cyclic adp-ribose secondary messenger signalling |
| WO2025150045A1 (en) | 2024-01-12 | 2025-07-17 | Gabriel Nussbaum | Bacterial targets, therapeutics, compositions, kits and methods of use in treating and/or preventing cancer |
| WO2026058262A1 (en) | 2024-09-16 | 2026-03-19 | Esther Priel | Substituted tri-phenyl derivative compounds, compositions comprising same and applications of same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| US3652761A (en) * | 1969-09-04 | 1972-03-28 | Corning Glass Works | Immunochemical composites and antigen or antibody purification therewith |
-
1970
- 1970-12-28 NL NL707018838A patent/NL154599B/xx not_active IP Right Cessation
-
1971
- 1971-12-10 US US00206952A patent/US3839153A/en not_active Expired - Lifetime
- 1971-12-13 CA CA129,950A patent/CA964560A/en not_active Expired
- 1971-12-13 ZA ZA718332A patent/ZA718332B/xx unknown
- 1971-12-15 IL IL38371A patent/IL38371A/xx unknown
- 1971-12-16 AU AU36986/71A patent/AU467394B2/en not_active Expired
- 1971-12-17 GB GB5873871A patent/GB1348938A/en not_active Expired
- 1971-12-22 FR FR7146179A patent/FR2120835A5/fr not_active Expired
- 1971-12-23 AT AT1108971A patent/AT320145B/de not_active IP Right Cessation
- 1971-12-23 SE SE7116552A patent/SE398557B/xx unknown
- 1971-12-23 FI FI3669/71A patent/FI54034C/fi active
- 1971-12-23 IT IT54975/71A patent/IT965020B/it active
- 1971-12-23 BR BR8553/71A patent/BR7108553D0/pt unknown
- 1971-12-24 CH CH1892971A patent/CH557030A/xx not_active IP Right Cessation
- 1971-12-26 EG EG552/71A patent/EG11604A/xx active
- 1971-12-27 BE BE777309A patent/BE777309A/nl not_active IP Right Cessation
- 1971-12-27 JP JP724140A patent/JPS5834783B1/ja active Granted
- 1971-12-27 ES ES398372A patent/ES398372A1/es not_active Expired
- 1971-12-27 DE DE19712164768 patent/DE2164768B2/de not_active Ceased
- 1971-12-28 DK DK639871A patent/DK150690C/da active
-
1982
- 1982-11-02 JP JP57193266A patent/JPS58117456A/ja active Pending
- 1982-11-02 JP JP57193265A patent/JPS58117455A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA964560A (en) | 1975-03-18 |
| BE777309A (nl) | 1972-04-17 |
| JPS58117455A (ja) | 1983-07-13 |
| CH557030A (de) | 1974-12-13 |
| JPS58117456A (ja) | 1983-07-13 |
| IL38371A0 (en) | 1972-02-29 |
| IL38371A (en) | 1974-06-30 |
| DE2164768A1 (de) | 1972-07-20 |
| NL7018838A (da) | 1972-06-30 |
| JPS5834783B1 (da) | 1983-07-28 |
| GB1348938A (en) | 1974-03-27 |
| AU3698671A (en) | 1973-06-21 |
| AU467394B2 (en) | 1975-11-27 |
| IT965020B (it) | 1974-01-31 |
| ZA718332B (en) | 1972-09-27 |
| SE398557B (sv) | 1977-12-27 |
| DK150690C (da) | 1988-06-06 |
| FR2120835A5 (da) | 1972-08-18 |
| EG11604A (en) | 1977-08-15 |
| AT320145B (de) | 1975-01-27 |
| BR7108553D0 (pt) | 1973-07-03 |
| ES398372A1 (es) | 1975-06-16 |
| NL154599B (nl) | 1977-09-15 |
| US3839153A (en) | 1974-10-01 |
| DE2164768B2 (de) | 1976-01-22 |
| FI54034C (fi) | 1978-09-11 |
| FI54034B (fi) | 1978-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK150690B (da) | Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse | |
| USRE31006E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
| Guesdon et al. | The use of avidin-biotin interaction in immunoenzymatic techniques. | |
| US4828985A (en) | Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods | |
| US3791932A (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
| US4235960A (en) | Competitive enzyme-linked immunoassay | |
| USRE29169E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
| US4232001A (en) | Methods and materials for detection of estrophilin | |
| US4427781A (en) | Particle agglutination immunoassay with agglutinator for determining haptens; PACIA | |
| US4477576A (en) | Antigen assay method and kit | |
| US4621048A (en) | Reagents containing an anti-ligand bound to an anti-enzyme and methods for employing said reagents in an immunoassy | |
| HOSODA et al. | Effect of bridge heterologous combination on sensitivity in enzyme immunoassay for cortisol | |
| EP0383313A2 (en) | Reagent for immunoassay, and kit containing the same | |
| US4693969A (en) | Reagent for use in a sandwich solid-phase enzyme-immunoassay and process for employing same | |
| EP0124366A2 (en) | Method of measuring biological ligands | |
| Mariotti et al. | A new solid phase immunoradiometric assay for antithyroid microsomal antibody | |
| US6555388B1 (en) | Binding protein capture assay | |
| US9891214B2 (en) | Immunological assay method | |
| JPH081436B2 (ja) | 生物学的液体中の遊離リガンドの測定方法および測定用キット | |
| JPH0731191B2 (ja) | チログロブリンを使用する甲状腺ホルモンの免疫定量法 | |
| EP0554458B1 (en) | Immunoassay and monoclonal antibody for determining diarrheal shellfish poisons | |
| EP0338045B1 (en) | Solid-phase non-separation enzyme assay | |
| EP0152305A2 (en) | Method of measuring biological ligand by utilising amylase | |
| Abdul-Ahad et al. | An enzyme-linked immunosorbent assay (ELISA) for bovine LH capable of monitoring fluctuations in baseline concentrations | |
| Pratt et al. | Specificity of immunoassays: II. Heterogeneity of specificity of antibodies in antisera used for steroid immunoassay and the selective blocking of less specific antibodies, including a new method for the measurement of immunoassay specificity |